<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>scpx_s1.htm
<DESCRIPTION>FORM S-1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>As filed with the Securities and Exchange Commission
on December&nbsp;27, 2024.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Registration Number 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNDER THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SCORPIUS HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 37%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 29%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>26-2844103</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of<BR>
incorporation or organization)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Primary Standard Industrial<BR>
Classification Code Number)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer<BR>
Identification No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>627 Davis Drive, Suite 300</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Morrisville, North Carolina 27560</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(919) 240-7133</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address, Including Zip Code, and Telephone Number,
Including Area Code, of Registrant&rsquo;s Principal Executive Offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Jeffrey Wolf</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>627 Davis Drive, Suite 300</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Morrisville, North Carolina 27560</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(919) 240-7133</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Name, Address, Including Zip Code, and Telephone Number,
Including Area Code, of Agent for Service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>with copies to:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center"><B>Leslie Marlow, Esq.<BR>
    Patrick J. Egan, Esq.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 12pt 0; text-align: center"><B>Hank Gracin, Esq.<BR>
    Melissa Palat Murawsky, Esq.<BR>
    Blank Rome LLP<BR>
    1271 Avenue of the Americas<BR>
    New York, NY 10020<BR>
    Phone: (212) 885-5000</B></P></TD>
    <TD STYLE="width: 51%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center"><B>Ron Ben-Bassat, Esq.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center"><B>Angela Gomes, Esq.&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center; color: #1D1D1F"><B>Sullivan &amp; Worcester
    LLP</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center; color: #1D1D1F"><B>1251 Avenue of the Americas</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center"><B>New York, NY 10020</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center"><B>Phone: (212) 660-5003</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Approximate date of commencement of proposed sale
to public:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">As soon as practicable after the effective date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If any of the securities being registered on this
Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act check the following box.&nbsp;<FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If this Form is filed to register additional securities
for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&nbsp;<FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If this Form is a post-effective amendment filed pursuant
to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective
registration statement for the same offering.&nbsp;<FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If this Form is a post-effective amendment filed pursuant
to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective
registration statement for the same offering.&nbsp;<FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is a
large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See
the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company&rdquo; and
&ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 26%"><FONT STYLE="font-size: 10pt">Large accelerated filer</FONT></TD>
    <TD STYLE="width: 36%"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 34%"><FONT STYLE="font-size: 10pt">Smaller reporting company</FONT></TD>
    <TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Accelerated filer</FONT></TD>
    <TD><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Emerging growth company</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided to Section 7(a)(2)(B) of the Securities Act.&nbsp;<FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to Section 8(a),
may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; color: #D2232A"><B>The information contained
in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement
filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities
and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 33%"><FONT STYLE="color: #D2232A"><B>PRELIMINARY PROSPECTUS</B></FONT></TD>
  <TD STYLE="text-align: center; width: 34%"><FONT STYLE="color: #D2232A"><B>SUBJECT TO COMPLETION</B></FONT></TD>
  <TD STYLE="text-align: right; width: 33%"><FONT STYLE="color: #D2232A"><B>DATED DECEMBER&nbsp;27, 2024</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; color: #D2232A"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><FONT STYLE="font-size: 14pt"><B>Up to 29,411,764&nbsp;Shares of
Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><FONT STYLE="font-size: 14pt"><B>Up to 29,411,764&nbsp;Pre-Funded
Warrants to purchase up to 29,411,764 Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><FONT STYLE="font-size: 14pt"><B>Up to 29,411,764&nbsp;Shares of
Common Stock Underlying such Pre-Funded Warrants</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image_004.jpg" ALT="A logo of a dinosaur&#10;&#10;Description automatically generated" STYLE="height: 148px; width: 230px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1in 0 12pt"><FONT STYLE="font-size: 18pt"><B>Scorpius Holdings, Inc.</B></FONT></P>

<P STYLE="font: 0.5pt Times New Roman, Times, Serif;  text-align: center; background-color: black">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">This is a firm commitment public offering (the &ldquo;Offering&rdquo;)
of up to 29,411,764 shares (the &ldquo;Shares&rdquo;) of common stock, par value $0.0002 per share (the &ldquo;Common Stock&rdquo;),
of Scorpius Holdings, Inc. based on an assumed public offering price of $0.34 per share (which is the last reported sales price of our
Common Stock on the NYSE American LLC (&ldquo;NYSE American&rdquo;) on December&nbsp;20, 2024).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We are also offering to certain purchasers, if any, whose purchase
of shares of Common Stock in this Offering would otherwise result in the purchaser, together with its affiliates and certain related parties,
beneficially owning more than 4.99% (or, at the election of such purchaser, 9.99%) of our outstanding Common Stock immediately following
the consummation of this Offering, the opportunity to purchase, if the purchaser so chooses, pre-funded warrants, (the &ldquo;Pre-Funded
Warrants&rdquo;), in lieu of shares of Common Stock that would otherwise result in the purchaser&rsquo;s beneficial ownership exceeding
4.99% (or, at the election of such purchaser, 9.99%) of our outstanding shares of Common Stock. Each Pre-Funded Warrant will be immediately
exercisable for one share of Common Stock and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.
The purchase price of each Pre-Funded Warrant will equal the price per share at which the shares of Common Stock are being sold to the
public in this Offering, minus $0.0002, and the exercise price of each Pre-Funded Warrant will be $0.0002 per share. For each Pre-Funded
Warrant we sell, the number of shares of Common Stock we are offering will be decreased on a one-for-one basis. This Offering also relates
to the shares of Common Stock issuable upon exercise of any Pre-Funded Warrants sold in this Offering. We refer to the Shares and Pre-Funded
Warrants to be sold in this Offering collectively as the &ldquo;Securities.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">You should read this prospectus, together with additional information
described under the heading &ldquo;<A HREF="#a_016">Where You Can Find More Information</A>&rdquo; carefully before you invest in any of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Our Common Stock is listed on NYSE American under the stock symbol
&ldquo;SCPX.&rdquo; On December&nbsp;20, 2024, the closing price of our Common Stock was $0.34 per share. In addition, there is no established
public trading market for the Pre-Funded Warrants and we do not expect a market to develop. Without an active trading market, the liquidity
of the Pre-Funded Warrants will be limited.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We are a &ldquo;smaller reporting company&rdquo; under applicable
rules of the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) and are subject to reduced public company reporting requirements
for this prospectus and future filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">On July&nbsp;17, 2024, we effected a reverse stock split at a ratio
of 1-for-200 (the &ldquo;2024 Reverse Stock Split&rdquo;). Unless otherwise noted, all historical share and per share information and
historical financial information included in this prospectus have been adjusted to reflect the 2024 Reverse Stock Split. All historical
share and per share information and historical financial information incorporated in this prospectus have not been restated to reflect
the 2024 Reverse Stock Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Investing in our Common Stock is highly speculative and involves
a high degree of risk. See &ldquo;<A HREF="#a_005">Risk Factors</A>&rdquo; beginning on page&nbsp;7 of this prospectus and under similar headings in
the other documents that are incorporated by reference into this prospectus</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any
representation to the contrary is a criminal offense.</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Per Share</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Per Pre-Funded Warrant</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%"><FONT STYLE="font-size: 10pt">Public offering price</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 13%"><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Underwriting discounts and commissions<SUP>(1)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Proceeds to us, before expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD><FONT STYLE="font-size: 10pt">Assumes no exercise of the option of the representative of the underwriters (&ldquo;ThinkEquity&rdquo;
or the &ldquo;representative&rdquo;) to purchase additional shares of our Common Stock as described below. See &ldquo;<A HREF="#a_013">Underwriting</A>&rdquo;
beginning on page 33 for a description of the compensation payable to the representative.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We have granted a 45-day option to the representative to purchase
from us, at the public offering price, less the underwriting discounts and commissions, up to 4,411,764&nbsp;additional shares of Common
Stock and/or 4,411,764&nbsp;Pre-Funded Warrants to purchase up to 4,411,764&nbsp;shares of Common Stock solely to cover over-allotments,
if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The underwriters expect to deliver the securities sold in this Offering
to the purchasers on or about &zwnj;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 16.2pt 0 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>ThinkEquity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: center">The date of this prospectus
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024<BR STYLE="clear: both"> </P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 16.2pt 0 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 16.2pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image_005.jpg" ALT="A close-up of a brochure&#10;&#10;Description automatically generated" STYLE="height: 810px; width: 625px"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 16.2pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif;   text-transform: uppercase; letter-spacing: 0.6pt; text-align: center">Table
of Contents</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 91%; padding-top: 2pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><A HREF="#a_001">About This Prospectu</A>s</FONT></TD>
    <TD STYLE="width: 9%; padding-top: 2pt; padding-bottom: 1pt; text-align: right">ii</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><A HREF="#a_002">Industry and Market Data</A></FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">iii</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><A HREF="#a_003">Prospectus Summary</A></FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><A HREF="#a_004">The Offering</A></FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><A HREF="#a_005">Risk Factors</A></FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><A HREF="#a_006">Selected Financial Data Reflecting The 2024 Reverse Stock Split</A></FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><A HREF="#a_007">Cautionary Note Regarding Forward-Looking Statements</A></FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><A HREF="#a_008">Use of Proceeds</A></FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><A HREF="#a_009">Capitalization</A></FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><A HREF="#a_010">Description of Securities We Are Offering</A></FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><A HREF="#a_011">Material United States Federal Income Tax Considerations</A></FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><A HREF="#a_012">Security Ownership of Certain Beneficial Owners and Management</A></FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><A HREF="#a_013">Underwriting</A></FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><A HREF="#a_014">Legal Matters</A></FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><A HREF="#a_015">Experts</A></FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><A HREF="#a_016">Where You Can Find More Information</A></FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">44</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><A HREF="#a_017">Incorporation of Certain Information By Reference</A></FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">45</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0"><B>The registration statement containing this prospectus, including
the exhibits to the registration statement, provides additional information about us and the securities being offered under this prospectus.
The registration statement, including the exhibits, can be read on our website and the website of the SEC. See &ldquo;<A HREF="#a_016">Where You Can Find More Information.</A>&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Information contained in, and that can be accessed through our web
site, <I>www.scorpiusbiologics.com,</I> shall not be deemed to be part of this prospectus or incorporated herein by reference and should
not be relied upon by any prospective investors for the purposes of determining whether to purchase the securities offered hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Unless the context otherwise requires, the terms &ldquo;we,&rdquo;
&ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company,&rdquo; &ldquo;Scorpius&rdquo; and &ldquo;our business&rdquo; refer to Scorpius
Holdings, Inc. and &ldquo;this offering&rdquo; refers to the offering contemplated in this prospectus.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt">i</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif;   text-transform: uppercase; letter-spacing: 0.6pt; text-align: center"><A NAME="a_001"></A>ABOUT
THIS PROSPECTUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We have not, and the underwriters have not, authorized anyone to
provide any information to you or to make any representations other than those contained in, or incorporated by reference into, this prospectus,
any amendment or supplement to this prospectus, or in any free writing prospectuses prepared by or on behalf of us or to which we have
referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others
may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions
where offers and sales are permitted. You should not assume that the information contained in this prospectus or any applicable prospectus
supplement is accurate on any date subsequent to the date set forth on the front cover of the document or that any information that we
have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this
prospectus or any applicable prospectus supplement is delivered, or securities are sold, on a later date. Our business, financial condition,
results of operations and prospects may have changed since the date on the front cover of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We may also file a prospectus supplement or post-effective amendment
to the registration statement of which this prospectus forms a part that may contain material information relating to this Offering. The
prospectus supplement or post-effective amendment may also add, update or change information contained in this prospectus. If there is
any inconsistency between the information in this prospectus and the applicable prospectus supplement or post-effective amendment, you
should rely on the applicable prospectus supplement or post-effective amendment, as applicable. Before purchasing any securities, you
should carefully read this prospectus, any prospectus supplement and any post-effective amendment together with the additional information
described under the heading &ldquo;<A HREF="#a_016">Where You Can Find More Information</A>&rdquo; and &ldquo;<A HREF="#a_017">Incorporation of Certain Information by Reference</A>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Neither we nor the underwriters have taken any action to permit
this Offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than
in the United States.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>For investors outside the United States: We have not, and the
underwriters have not, done anything that would permit this Offering or possession or distribution of this prospectus or any applicable
free writing prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside
the United States who come into possession of this prospectus and any applicable free writing prospectus must inform themselves, and observe
any restrictions relating to, the offering and the distribution of this prospectus outside the United States.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">This prospectus contains summaries of certain provisions contained
in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries
are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be
filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may
obtain copies of those documents as described below under the section entitled &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt">ii</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;   text-transform: uppercase; letter-spacing: 0.6pt; text-align: center"><A NAME="a_002"></A>INDUSTRY
AND MARKET DATA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Unless otherwise indicated, information in this prospectus concerning
economic conditions, our industry, our markets and our competitive position is based on a variety of sources, including information from
third-party industry analysts and publications and our own estimates and research. Some of the industry and market data contained in this
prospectus are based on third-party industry publications. This information involves a number of assumptions, estimates and limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The industry publications, surveys and forecasts and other public
information generally indicate or suggest that their information has been obtained from sources believed to be reliable. We believe this
information is reliable as of the applicable date of its publication, however, we have not independently verified the accuracy or completeness
of the information included in or assumptions relied on in these third-party publications. In addition, the market and industry data and
forecasts that may be included in this prospectus, any post-effective amendment or any prospectus supplement may involve estimates, assumptions
and other risks and uncertainties and are subject to change based on various factors, including those discussed under the heading &ldquo;<A HREF="#a_005">Risk Factor</A>s&rdquo; contained in this prospectus or any document incorporated herein by reference, any post-effective amendment and the applicable
prospectus supplement. Accordingly, investors should not place undue reliance on this information.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt">iii</P>


<!-- Field: Page; Sequence: 8; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  text-transform: uppercase; letter-spacing: 0.6pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding: 10pt; border: Black 0.5pt solid">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  text-transform: uppercase; letter-spacing: 0.6pt; text-align: center"><A NAME="a_003"></A>&nbsp;PROSPECTUS
SUMMARY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><I>The following summary highlights information contained elsewhere
in this prospectus or incorporated by reference herein and does not contain all the information that may be important to purchasers of
our securities. Prospective purchasers of our securities should carefully read the entire prospectus and any applicable prospectus supplement,
including the risks of investing in our securities discussed under the heading &ldquo;<A HREF="#a_005">Risk Factors</A>&rdquo; contained in this prospectus
and under similar headings in the other documents that are incorporated by reference into this prospectus. Prospective purchasers of our
securities should also carefully read the information incorporated by reference into this prospectus, including our financial statements,
and the exhibits to the registration statement of which this prospectus is a part.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Our Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">We are a contract development and manufacturing organization (&ldquo;CDMO&rdquo;)
that provides a comprehensive range of biologics manufacturing services from process development to Current Good Manufacturing Practices
(&ldquo;cGMP&rdquo;) clinical and commercial manufacturing of biologics for the biotechnology and biopharmaceutical industries. Scorpius
pairs cGMP biomanufacturing and quality control expertise with cutting edge capabilities in immunoassays, molecular assays, and bioanalytical
methods to support the production of cell- and gene-based therapies as well as large molecule biologics. Our services include clinical
and commercial drug substance manufacturing, release and stability testing and variety of process development services, including upstream
and downstream development and optimization, analytical method development, cell line development, testing and characterization. Our San
Antonio, TX facility commenced operations in October 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; ">Recent Developments</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">December Private Placement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">On December&nbsp;5, 2024, we entered into a Securities Purchase
Agreement (the &ldquo;Purchase Agreement&rdquo;) with certain institutional investors (collectively, the &ldquo;Investors&rdquo;), pursuant
to which we agreed to issue, in a private placement offering (the &ldquo;December Note Offering&rdquo;), upon the satisfaction of certain
conditions specified in the Purchase Agreement, 9% senior secured convertible notes (the &ldquo;Secured Convertible Notes&rdquo;) in the
aggregate principal amount of $13,388,889, and warrants (the &ldquo;December Warrants&rdquo;) to purchase up to an aggregate amount of
13,388,889 shares of Common Stock, to the Investors for an aggregate purchase price of $12,050,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The December Note Offering closed on December&nbsp;6, 2024 (the
&ldquo;Closing Date&rdquo;). We received net proceeds from the December Note Offering of approximately $3.3 million, net of the amount
of $8.5 million of the proceeds of the December Note Offering that we agreed to use to pay the Investors pursuant to the Purchase Agreement
to repurchase pre-funded warrants held by the Investors (the &ldquo;Repurchased Pre-Funded Warrants&rdquo;), which amount was paid to
the Investors at the closing of the December Note Offering, and approximately $226,000 to redeem the November 2024 Note (as defined below),
including all principal and accrued interest. In connection with the December Note Offering, we agreed to reimburse the Investors for
all costs and expenses incurred by them or their affiliates in connection with the transactions contemplated by the Purchase Agreement,
up to a total amount of $50,000. ThinkEquity acted as placement agent in the December Note Offering. In connection with the closing of
the December Note Offering, the Company paid a placement fee of $285,000 to ThinkEquity, equal to 8% of the net proceeds of the December
Note Offering paid to us, net of the amount used to repurchase the Repurchased Pre-Funded Warrants and the amount of the original issue
discount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">On the Closing Date, the Company, each of the Company&rsquo;s domestic
subsidiaries and the Investors also entered into a Security Agreement (the &ldquo;Security Agreement&rdquo;), pursuant to which the Company
and each of the Company&rsquo;s domestic subsidiaries granted security interests in the Collateral (as such term is defined in the Security
Agreement) to secure the obligations of the Company under the Secured Convertible Notes and the Purchase Agreement. Each of the Company&rsquo;s
domestic subsidiaries also executed and delivered a Subsidiary Guarantee on the Closing Date, pursuant to which they agreed to guarantee
the Company&rsquo;s obligations under the Secured Convertible Notes and act as surety for payment of the Secured Convertible Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

</DIV>
<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  "></P>
<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<DIV STYLE="padding: 10pt; border: Black 0.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The Secured Convertible Notes mature on the third anniversary of
their date of issuance, or December&nbsp;6, 2027, unless prior thereto there is an event of default, and bear interest at a rate of 9%
per annum payable in cash on the first business day of each fiscal quarter beginning January 2, 2025. The Secured Convertible Notes are
convertible, at the option of the holder, at any time, into a number of shares of Common Stock equal to the principal amount of the Secured
Convertible Note plus all accrued and unpaid interest at a conversion price equal to $0.50 (the &ldquo;Conversion Price&rdquo;), subject
to adjustment for any stock splits, stock dividends, recapitalizations and similar events and subject to an Exchange Cap (as defined below)
and other limitations. The Secured Convertible Notes contain customary events of default, including the failure of Jeffrey Wolf to remain
as our Chief Executive Officer, unless an individual reasonably acceptable to the Investors has been appointed to replace Mr. Wolf within
thirty (30) days of such occurrence, unless the Investors extend such deadline for an additional thirty (30) days at their sole discretion.
If an event of default occurs, until it is cured, the Investors may increase the interest rate applicable to the Secured Convertible Note
to 15% per annum. If an event of default occurs, the Investors may require us to redeem (regardless of whether such event of default has
been cured) all or any portion of the Secured Convertible Notes. Subject to limited exceptions set forth in the Secured Convertible Notes,
the Secured Convertible Notes prohibit us and, as applicable, our subsidiaries from incurring any new indebtedness. The Secured Convertible
Notes also provide that we shall, while the Secured Convertible Notes remain outstanding, maintain a net monthly cash burn of not more
than $1,800,000, calculated on an average trailing-three-month basis, decreasing by increments of $500,000 every three-months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The Secured Convertible Notes are redeemable by us at a redemption
price equal to 110% of the sum of the principal amount to be redeemed plus accrued interest, if any. While the Secured Convertible Notes
are outstanding, if we enter into a Subsequent Placement (as such term is defined in the Purchase Agreement and which would include this
Offering), each of the Investors shall have the right, in their sole discretion, to require that we redeem all, or any portion, of the
amount due under their Secured Convertible Note in an amount not in excess of the Investor&rsquo;s pro rata amount of 25% of the gross
proceeds of such Subsequent Placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The December Warrants expire five years from their date of issuance.
The December Warrants are exercisable, at the option of the holder, at any time, for up to an aggregate of 13,388,889 shares of Common
Stock at an exercise price equal to $0.50 (the &ldquo;Exercise Price&rdquo;), subject to adjustment for any stock splits, stock dividends,
recapitalizations, and similar events and subject to the Exchange Cap. The Secured Convertible Notes and the December Warrants provide
for the Conversion Price and the Exercise Price, respectively, to be adjusted in various circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The December Warrants provide for cashless exercise under certain
circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">The number of shares of Common Stock that may be issued upon conversion
of the Secured Convertible Notes and exercise of the December Warrants, and inclusive of any shares issuable under and in respect of the
Purchase Agreement, is subject to an exchange cap (the &ldquo;Exchange Cap&rdquo;) of 865,820 shares, which is 19.99% of the outstanding
number of shares of our Common Stock on the Closing Date, unless we obtain approval from our stockholders to issue shares of Common Stock
to the holders upon conversion of the Secured Convertible Notes and exercise of the Warrants in excess of the Exchange Cap. If the Secured
Convertible Notes were to be fully converted into Conversion Shares at the Conversion Price initially in effect, assuming no Exchange
Cap, we would issue 26,777,778 Conversion Shares plus an additional 7,230,000 shares of Common Stock if interest and the Make-Whole Amount
(as such term is defined in the Secured Convertible Notes) are also converted into shares of Common Stock. In addition, under the terms
of the Secured Convertible Notes and the December Warrants, the Investors may not convert the Secured Convertible Notes or exercise the
December Warrants to the extent such conversion or exercise would cause such Investor, together with its affiliates and attribution parties,
to beneficially own a number of shares of Common Stock that would exceed 4.99%, of our then outstanding Common Stock following such conversion
or exercise.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  "></P>

</DIV>
<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  "></P>
<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; ">&nbsp;</P>

<DIV STYLE="padding: 10pt; border: Black 0.5pt solid">

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; ">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif">November 2024 Note</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">On November 27, 2024, we issued a non-convertible promissory note
(the &ldquo;November 2024 Note&rdquo;) in the principal amount of $225,000 to one of the Investors (the &ldquo;Holder&rdquo;). The November
2024 Note accrues interest at the rate of 5% per annum and matures on the earliest of: (i) December 15, 2024; (ii)&nbsp;the
consummation of a Corporate Event (as such term is defined in the November 2024 Note); or (iii)&nbsp;when, upon or after the occurrence
of an event of default under the November 2024 Note. The November 2024 Note contains customary events of default, including if we or any
of our subsidiaries, individually or in the aggregate, fail to pay indebtedness in excess of $150,000 due to any third party, subject
to certain exceptions, or if an event of default occurs under any of our other outstanding promissory notes. If at any time while the
November 2024 Note is outstanding we consummate a subsequent Financing (as such term is defined in the November 2024 Note), the Holder
shall have the right, it its sole discretion, to require that we redeem the entire outstanding balance of the November 2024 Note, together
with all accrued interest thereon, using up to 100% of the gross proceeds of such Financing. The November&nbsp;2024 Note was repaid using
the proceeds from the December Note Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">August 2024 Public Offering</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">On August 19, 2024, we consummated a public offering (the &ldquo;August
Offering&rdquo;) of 2,428,000 shares of Common Stock and 11,947,000 pre-funded warrants to purchase up to 11,947,000 shares
of Common Stock (the &ldquo;August PFWs&rdquo;), including 1,875,000 ;option pre-funded warrants to purchase up to 1,875,000 shares
of Common Stock issued upon the exercise of the representative&rsquo;s over-allotment option (the &ldquo;August Option PFWs&rdquo;) for
a purchase price of $1.00 per share of Common Stock, a purchase price of $0.9998 per August PFW, and an exercise price of $0.0002
per August PFW and August Option PFW, resulting in aggregate gross proceeds of approximately $14.4 million, before deducting underwriting
discounts and other offering expenses. Each August PFW and August Option PFW is exercisable for one share of Common Stock. ThinkEquity
served as representative of the several underwriters named in the Underwriting Agreement that we entered into on August&nbsp;16, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">2024 Reverse Stock Split</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">On July 17, 2024, we effected a 1-for-200 reverse stock split of
our outstanding shares of Common Stock (the &ldquo;2024 Reverse Stock Split&rdquo;). The 2024 Reverse Stock Split did not impact the number
of authorized shares of Common Stock, which remained at 250,000,000 shares. Unless otherwise noted, all historical share and per share
information and historical financial information included in this prospectus have been adjusted to reflect the 2024 Reverse Stock Split.
Certain historical share and per share information and historical financial information incorporated by reference into this prospectus
have not been restated to reflect the 2024 Reverse Stock Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Related Party Notes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">On January 26, 2024 in accordance with the terms of that certain
Asset and Equity Interests Purchase Agreement, dated December 11, 2023 (the &ldquo;Asset Purchase Agreement&rdquo;), with Elusys Holdings,
Inc., a company controlled by Jeffrey Wolf, our Chief Executive Officer and Chairman of the Board of Directors (&ldquo;Elusys Holdings&rdquo;),
Elusys Holdings purchased from us a convertible promissory note in the aggregate amount of $2,250,000 (the &ldquo;Original Convertible
Note&rdquo;), the conversion of which was subject to both Elusys Holdings&rsquo; election and obtaining stockholder approval as may be
required by the applicable rules and regulations of NYSE American of the issuance of shares of our Common Stock upon such conversion.
The Original Convertible Note bore interest at a rate of 1% per annum, was to mature on the one-year anniversary of its issuance and converted
into shares of our Common Stock at the option of Elusys Holdings only if the applicable stockholder approval of the issuance of such shares
of Common Stock issuable upon conversion of the Original Convertible Note was obtained prior to the maturity date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<DIV STYLE="padding: 10pt; border: Black 0.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">On May 1, 2024, we entered into a Note Purchase Agreement with Elusys
Holdings, pursuant to which Elusys Holdings loaned us $750,000 and we (i)&nbsp;issued to Elusys Holdings a 1% non-convertible promissory
note due July&nbsp;1, 2024 in the principal amount of $750,000 (the &ldquo;New Note&rdquo;) for $750,000 in cash and (ii)&nbsp;issued
to Elusys Holdings an amended and restated 1% convertible promissory note in the principal amount of $2,250,000 (the &ldquo;Restated Note&rdquo;)
in exchange for the Original Convertible Note. The Restated Note bears interest at a rate of 1% per annum, matures on September 1, 2025
and will convert into shares of our Common Stock at the option of Elusys Holdings only if stockholder approval as may be required by the
applicable rules and regulations of NYSE American of the issuance of all of the shares of Common Stock issuable upon conversion of the
Restated Note is obtained prior to the maturity date and any required approval of NYSE American of such share issuance is obtained. The
conversion price of the Restated Note was initially equal to 110% of the volume weighted average price (VWAP) of Common Stock for the
seven trading days prior to December 11, 2023 which was $0.39109; however, Section&nbsp;2(b) of the Restated Note provided that if we
consummated a public financing, subject to certain exceptions, within sixty days of May&nbsp;1, 2024, the conversion price would be adjusted
to be 110% of the per share purchase price of the Common Stock in such public financing (with such adjustment only being made upon the
first financing in the event of multiple financings during the foregoing period). Based on the public offering that we consummated in
May&nbsp;2024, after adjustment for the 2024 Reverse Stock Split, the conversion price of the Restated Note was adjusted to $22.00, allowing
the holder of the Restated Note to convert the Restated Note into up to 103,908&nbsp;shares of Common Stock (including the principal amount
of $2,250,000 and all accrued interest thereon calculated as of the date of maturity.) At the 2024 Annual Meeting, our stockholders approved
the issuance of 103,908&nbsp;shares of Common Stock issuable upon full conversion of the Restated Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">On July 16, 2024, we entered into an Amendment to the New Note that
extended its maturity date to July 31, 2024 and provided that the New Note would be secured by a lien on our assets, subordinate to any
secured lien that may be requested by a lender in connection with debt. On July&nbsp;30, 2024, Elusys Holdings forgave repayment of the
New Note in exchange for an amendment to the Asset Purchase Agreement to eliminate the payment of any royalty fees by Elusys Holdings
to us and instead provide for a cash payment to us of $2.5 million on or prior to December 31, 2028.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Corporate Information&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We were incorporated under the laws of the State of Delaware on
May 12, 2017. Our principal executive offices are located at 627 Davis Drive, Suite 300, Morrisville, North Carolina 27560. Our telephone
number is (610) 727-4597.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Our website address is&nbsp;<I>www.scorpiusbiologics.com</I>. The
information contained in, or accessible through, our website does not constitute a part of this prospectus. You should not rely on any
such information in making your decision whether to purchase our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

</DIV>
<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  "></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<DIV STYLE="padding: 10pt; border: Black 0.5pt solid">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  text-transform: uppercase; letter-spacing: 0.6pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; letter-spacing: 0.6pt; text-align: center"><A NAME="a_004"></A>THE
OFFERING</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; width: 31%; padding-bottom: 12pt"><FONT STYLE="font-size: 10pt"><B>Shares being offered</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 68%; padding-bottom: 12pt"><FONT STYLE="font-size: 10pt">29,411,764&nbsp;Shares (or 33,823,528 Shares if the representative&nbsp;&nbsp;exercises its option to purchase additional shares in full) of Common Stock based on an assumed public offering price of $0.34 per share (which is the last reported sale price of our Common Stock on NYSE American on December&nbsp;20, 2024).</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-bottom: 12pt"><FONT STYLE="font-size: 10pt"><B>Pre-Funded Warrants offered by us</B></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 12pt"><FONT STYLE="font-size: 10pt">We are also offering up to 29,411,764&nbsp;Pre-Funded Warrants to purchase up to 29,411,764&nbsp;shares of Common Stock in lieu of shares of Common Stock to any purchaser whose purchase of shares of Common Stock in this Offering would otherwise result in such purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the purchaser&rsquo;s election, 9.99%) of our outstanding Common Stock immediately following the consummation of this Offering. Each Pre-Funded Warrant will be exercisable for one share of Common Stock, will have an exercise price of $0.0002 per share, will be immediately exercisable, and will not expire prior to exercise. This prospectus also relates to the offering of the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants. For each Pre-Funded Warrant that we sell, the number of Shares that we are selling will be decreased on a one-for-one basis.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-bottom: 12pt"><FONT STYLE="font-size: 10pt"><B>Number of shares of Common Stock outstanding immediately before this Offering</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 12pt"><FONT STYLE="font-size: 10pt">4,868,268&nbsp;issued and outstanding as of December&nbsp;20, 2024.</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-bottom: 12pt"><FONT STYLE="font-size: 10pt"><B>Number of shares of Common Stock to be outstanding after this Offering<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 12pt"><FONT STYLE="font-size: 10pt">34,280,032&nbsp;shares (or 38,691,796 shares if the representative exercises its option to purchase additional shares in full) based on an assumed public offering price of $0.34 per share (which is the last reported sale price of our Common Stock on NYSE American on December&nbsp;20, 2024) and assumes no sale of Pre-Funded Warrants, which, if sold, would reduce the number of Shares that we are offering on a one-for-one basis.</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-bottom: 12pt"><FONT STYLE="font-size: 10pt"><B>Option to purchase additional shares and Pre-Funded Warrants</B></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 12pt"><FONT STYLE="font-size: 10pt">We have granted a 45-day option to the representative to purchase from us, at the public offering price, less the underwriting discounts and commissions, up to 4,411,764 additional shares of Common Stock and/or 4,411,764&nbsp;Pre-Funded Warrants solely to cover over-allotments, if any.</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-bottom: 12pt"><FONT STYLE="font-size: 10pt"><B>Use of proceeds</B></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We expect to receive net proceeds, after deducting the underwriting
    discounts and commissions and estimated expenses payable by us, of approximately $6.3&nbsp;million (or approximately $7.3&nbsp;million
    if the representative exercises its option to purchase additional shares in full), which assumes that the Investors holding the Secured
    Convertible Notes require that we use $2.5&nbsp;million from the proceeds of this Offering to repay a portion of the Secured Convertible
    Notes.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We currently intend to use the net proceeds from this Offering to
    fund working capital and general corporate purposes. See &ldquo;<A HREF="#a_008">Use of Proceeds</A>&rdquo;.</P></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-bottom: 12pt"><FONT STYLE="font-size: 10pt"><B>Trading</B></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 12pt"><FONT STYLE="font-size: 10pt">Our Common Stock is listed on NYSE American under the stock symbol &ldquo;SCPX.&rdquo;</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-bottom: 12pt"><FONT STYLE="font-size: 10pt"><B>Risk factors</B></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing in our Common Stock involves a high degree of risk. See &ldquo;<A HREF="#a_005">Risk Factors</A>&rdquo; beginning on page&nbsp;7 of this prospectus, and the other information included, or incorporated by reference, in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our securities</FONT></TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</DIV>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<DIV STYLE="padding: 10pt; border: Black 0.5pt solid">

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD><FONT STYLE="font-size: 10pt">The numbers of shares of our Common Stock to be outstanding before and upon completion of this Offering
are based on 4,868,268 shares of our Common Stock outstanding as of December&nbsp;20, 2024 and excludes the following:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">30,738 shares of Common Stock issuable upon exercise of stock options outstanding, at a weighted-average
exercise price of $678.21 per share;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">1,500,000 shares of Common Stock issuable upon exercise of pre-funded warrants outstanding, at an exercise
price of $0.0002 per share;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">299,112 shares of Common Stock issuable upon exercise of common warrants outstanding, at an exercise
price of $24.00 per share;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">103,908 shares of Common Stock issuable upon conversion in full (including accrued interest thereon
calculated as of the date of maturity) of the Restated Note (the conversion of which is subject to both Elusys Holdings&rsquo; election
and any required approval of NYSE American of such share issuance); </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Up to 47,396,667 shares of Common Stock issuable upon conversion in full (including make-whole amounts)
of the Secured Convertible Notes and upon exercise of the December Warrants; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">156,269 shares of our Common Stock that are available for future issuance under our stock incentive
plans or shares that will become available under our stock incentive plans (after giving effect to the amendment to our 2018 Equity Incentive
Plan approved by our stockholders on July 15, 2024 to increase by 150,000 the number of shares available for grant under our 2018 Equity
Incentive Plan).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Unless otherwise indicated, this prospectus reflects and assumes
the following:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">no exercise of outstanding options or warrants described above;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">no conversion of the Restated Note and Secured Convertible Notes;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">no sale of any Pre-Funded Warrants; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">no issuance of the warrants issues to the representative (the &ldquo;Representative&rsquo;s Warrants&rdquo;);
and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">no exercise by the representative of its option to purchase additional shares of our Common Stock.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">All share and per share amounts of Common Stock presented in this
prospectus have been retroactively adjusted to reflect the 2024 Reverse Stock Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif;   text-transform: uppercase; letter-spacing: 0.6pt; text-align: center"><A NAME="a_005"></A>RISK
FACTORS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><I>Investing in our securities involves a high degree of risk. You
should consider carefully the risks described below, together with all of the other information included or incorporated by reference
into this prospectus, including the risks and uncertainties discussed under &ldquo;Risk Factors&rdquo; in our Annual Report on Form 10-K
for the year ended December 31, 2023, Quarterly Reports on Form 10-Q, and Current Reports on Form&nbsp;8-K, which have been filed with
the SEC and are incorporated by reference into this prospectus, as well as any updates thereto contained in subsequent filings with the
SEC or any free writing prospectus, before deciding whether to purchase our securities in this Offering. All of these risk factors are
incorporated herein in their entirety. The risks described below and incorporated by reference are material risks currently known, expected
or reasonably foreseeable by us. However, the risks described below and incorporated by reference are not the only ones that we face.
Additional risks not presently known to us or that we currently deem immaterial may also affect our business, operating results, prospects
or financial condition. If any of these risks actually materialize, our business, prospects, financial condition, and results of operations
could be seriously harmed. This could cause the trading price of our Common Stock to decline, resulting in a loss of all or part of your
investment.</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; ">Risks Related to this Offering and Our Common Stock</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; ">Our consolidated financial statements have been
prepared assuming that we will continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We had an accumulated deficit of $277.8 million as of September
30, 2024 and a net loss of approximately $24.5 million for the nine months ended September 30, 2024. We had an accumulated deficit of
$254.4 million as of December 31, 2023 and a net loss of approximately $46.8 million for the year ended December 31, 2023. To date, we
have not generated significant revenue or positive cash flows from operations. We expect to incur significant expenses and continued losses
from operations for the foreseeable future, and we do not expect our cash and cash equivalents and short-term investments, including proceeds
from the August Offering and the proceeds of approximately $6.3&nbsp;million that we expect to raise in this Offering (or approximately
$7.3&nbsp;million if the representative exercises its option to purchase additional shares in full), to be sufficient to fund our operations
beyond April 2025 (or May&nbsp;2025 if the representative exercises its option to purchase additional shares in full) unless our revenue
significantly increases from past historical revenue. Our estimates of our runway are dependent upon our estimates of the ability of our
customers to make timely payments of amounts owed to us which recently has not occurred. We expect our expenses to increase in connection
with our ongoing activities, particularly as we ramp up operations in our in-house bioanalytic, process development and manufacturing
facility in San Antonio, TX. Our unaudited financial statement for the three and nine months ended September 30, 2024 and our audited
financial statements for the fiscal year ended December 31, 2023 were prepared under the assumption that we will continue as a going concern;
however, we have incurred significant losses from operations to date and we expect our expenses to increase in connection with our ongoing
activities. These factors raise substantial doubt about our ability to continue as a going concern for one year after the financial statements
are issued. Our auditors also included an explanatory paragraph in their report on our financial statements as of and for the year ended
December 31, 2023 with respect to this uncertainty. There can be no assurance that funding will be available on acceptable terms on a
timely basis, or at all. The various ways that we could raise capital carry potential risks. Any additional sources of financing will
likely involve the issuance of our equity securities, which will have a dilutive effect on our stockholders. Any debt financing, if available,
may involve restrictive covenants that may impact our ability to conduct our business. If we raise funds through collaborations and licensing
arrangements, we might be required to relinquish significant rights to our technologies or tests or grant licenses on terms that are not
favorable to us. If we do not succeed in raising additional funds on acceptable terms or at all, we may be unable to build our planned
Kansas facility or develop any new product candidates that we acquire. As such, we cannot conclude that such plans will be effectively
implemented within one year after the date that the financial statements incorporated by reference into this prospectus were filed with
the SEC and there is uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises
substantial doubt about our ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">In addition to requiring additional financing, in order to successfully
continue our business we will need to expand our customer base beyond the limited number of customers we currently have, and there can
be no assurance we will be successful in doing so. Though we continue to expand our customer base, we remain dependent on a limited number
of customers for a substantial majority of our revenues. For the three and nine months ended September 30, 2024, we recognized $0.8 million
and $5.0 million in CDMO revenue, all of which was primarily derived from three customers who each represented over 10% of the total recognized
revenue. For the year ended December 31, 2023, revenue from two customers accounted for 86% of our total recognized process development
revenue. One former customer who migrated to a larger CDMO for commercial manufacture of their product accounted for &nbsp;74% of our
process development revenue for the fiscal year ended December 31, 2023. The loss of, or a significant reduction of business from, any
of our primary customers will have a material adverse effect on our business, financial condition, and results of operation unless we
are able to replace such customers with other primary customers.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">We will need additional future financing which
may not be available on acceptable terms, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We will need to raise additional capital to fund our operations
and to repay amounts due under the Secured Convertible Notes, and we cannot be certain that funding will be available to us on acceptable
terms on a timely basis, or at all. As of December&nbsp;20, 2024, our cash and cash equivalents and short-term investments were approximately
$1.8&nbsp;million. Even with the proceeds of approximately $6.3 million that we expect to raise in this Offering (or approximately $7.3&nbsp;million
if the representative exercises its option to purchase additional shares in full), which assumes that the Investors holding the Secured
Convertible Notes require that we use $2.5&nbsp;million from the proceeds of this Offering to repay a portion of the Secured Convertible
Notes, our cash, together with the proceeds of this Offering, is not expected to last beyond April&nbsp;2025 (or May 2025 if the representative
exercises its option to purchase additional shares in full) unless our revenue significantly increases from past historical revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">There are currently no other commitments by any person for future
financing. Our securities may be offered to other investors in other offerings at a price lower than the price per share offered in this
Offering, or upon terms which may be deemed more favorable than those offered to investors in this Offering. Our ability to raise capital
through the sale of securities may be limited by our inability to utilize a registration statement on Form S-3 to raise capital due to
the late filing of our 2023 Annual Report and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, and due to various
rules of NYSE American that place limits on the number and dollar amount of securities that we may sell. To the extent that we raise additional
funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve
restrictive covenants that may impact our ability to conduct our business. If we are unable to raise additional capital in sufficient
amounts or on terms acceptable to us, we may have to restructure our Company including a work force reduction, or initiate steps to cease
operations or liquidate our assets.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Our failure to meet the continued listing requirements
of NYSE American could result in a de-listing of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Our shares of Common Stock are currently listed on NYSE American.
On June 14, 2024, we received notice from the NYSE Regulation that it had suspended trading of our Common Stock on NYSE American and determined
to commence proceedings to delist our Common Stock from NYSE American as a result of its determination that we were no longer suitable
for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of our Common Stock. Our Common
Stock began to be quoted on the OTC Markets system on June 17, 2024. On July 17, 2024, we effected the 2024 Reverse Stock Split at a ratio
of 1-for-200, to increase the selling price of our Common Stock in order to regain compliance with the requirements and policies of NYSE
American. On July 29, 2024, NYSE American notified us that it had withdrawn its delisting determination and our Common Stock resumed trading
on NYSE American on Friday, August 2, 2024, under the symbol &ldquo;SCPX.&rdquo; However, there can be no assurance that the market price
of our Common Stock following the 2024 Reverse Stock Split will remain at a level that will be sufficient to meet any requirements and
policies of NYSE American or that our Common Stock will remain listed on NYSE American.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">In addition, on April 17, 2024, we received an official notice of
noncompliance from NYSE Regulation stating that we were not in compliance with the NYSE American continued listing standards under the
timely filing criteria included in Section 1007 of the NYSE American Company Guide due to the failure to timely file our 2023 Annual Report
on Form 10-K by the applicable filing due date. On May 21, 2024, we received an official notice of noncompliance from NYSE Regulation
stating that we were not in compliance with NYSE American continued listing standards under the timely filing criteria included in Section
1007 of the NYSE American Company Guide due to the failure to timely file our Quarterly Report on Form 10-Q for the quarter ended March
31, 2024 by the applicable filing due date. Upon the subsequent filing of the 2023 Annual Report on Form 10-K and the Quarterly Report
on Form 10-Q we received a notice that we had cured such filing delinquencies.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Investors may experience dilution of their ownership
interests because of the future issuance of additional shares of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">In the future, we may issue additional authorized but previously
unissued equity securities, resulting in the dilution of the ownership interests of our present stockholders. We may also issue additional
shares of our Common Stock or other securities that are convertible into or exercisable for our Common Stock in connection with hiring
or retaining employees, future acquisitions, future sales of our securities for capital raising purposes, or for other business purposes
and some of these issuances may be at a price (or exercise prices) below the price at which shares of our Common Stock are currently trading.
The future issuance of any such additional shares of Common Stock may create downward pressure on the trading price of our Common Stock.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Substantial amounts of our outstanding shares may
be sold into the market when lock-up or market standstill periods ends. If there are substantial sales of shares of our Common Stock,
the price of our Common Stock could decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The price of our Common Stock could decline if there are substantial
sales of our Common Stock, particularly sales by our directors, executive officers and significant stockholders, or if there is a large
number of shares of our Common Stock available for sale and the market perceives that sales will occur. After this Offering, if the maximum
amount of Shares and no Pre-Funded Warrants are sold, we will have 34,280,032 outstanding shares of our Common Stock (or 38,691,796 shares
if the representative exercises its option to purchase additional shares in full), based on the number of shares outstanding as of December&nbsp;20,
2024. All of the shares of Common Stock sold in this Offering will be available for sale in the public market.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Our management has broad discretion in using the
net proceeds from this Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We intend to use the net proceeds from this Offering to fund working
capital and general corporate purposes. See &ldquo;<A HREF="#a_008">Use of Proceeds</A>.&rdquo; We will have broad discretion in the timing of the expenditures
and application of proceeds received in this Offering. You will not have the opportunity, as part of your investment decision, to assess
whether the proceeds are being used in a manner which you may consider most appropriate. Our management might spend a portion or all of
the net proceeds from this Offering in ways that our stockholders do not desire or that might not yield a favorable return. The failure
by our management to apply these funds effectively could harm our business. Furthermore, you will have no direct say on how our management
allocates the net proceeds of this Offering.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Because we do not anticipate paying any cash dividends
on our Common Stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We have never declared or paid any cash dividends on our Common
Stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do
not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of our Common
Stock would be your sole source of gain on an investment in our Common Stock for the foreseeable future.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">This offering may cause the trading price of our
Common Stock to decrease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The price per share, together with the number of shares of Common
Stock we issue if this Offering is completed, may result in an immediate decrease in the market price of our Common Stock. This decrease
may continue after the completion of this Offering.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  "></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif">There is no public market for the Pre-Funded Warrants
being offered in this Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">There is no established public trading market for the Pre-Funded
Warrants, and we do not expect a market to develop. In addition, we do not intend to apply to list the Pre-Funded Warrants on any national
securities exchange or other nationally recognized trading system. Without an active market, the liquidity of the Pre-Funded Warrants
will be limited.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Except as provided in the Pre-Funded Warrants,
holders of the Pre-Funded Warrants offered hereby will have no rights as common stockholders with respect to the shares our Common Stock
underlying the Pre-Funded Warrants until such holders exercise their Pre-Funded Warrants and acquire our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Until holders of the Pre-Funded Warrants acquire shares of our Common
Stock upon exercise thereof, such holders will have no rights with respect to the shares of our Common Stock underlying such Pre-Funded
Warrants, except to the extent that holders of such Pre-Funded Warrants will have certain rights to participate in distributions or dividends
paid on our Common Stock as set forth in the Pre-Funded Warrants. Upon exercise of the Pre-Funded Warrants, the holders will be entitled
to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise date.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">The Pre-Funded Warrants are speculative in nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Holders of the Pre-Funded Warrants may acquire shares of Common
Stock issuable upon exercise of such Pre-Funded Warrants at an exercise price of $0.0002 per share of Common Stock. There can be no assurance
that the market value of the Pre-Funded Warrants will equal or exceed their public offering price.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Even though the 2024 Reverse Stock Split increased
the market price of our Common Stock, there can be no assurance that our increased stock price will remain at a price that will be sufficient
in order to meet any continued requirements and policies of NYSE American or that our Common Stock will remain listed on NYSE American.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The trading of our Common Stock resumed on NYSE American on August
2, 2024 after we effected the 2024 Reverse Stock Split. There can be no assurance that the increased stock price resulting from the 2024
Reverse Stock Split will be sufficient in order to continue to meet any requirements and policies of NYSE American or that our Common
Stock will remain listed on NYSE American.</P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif;   text-transform: uppercase; letter-spacing: 0.6pt; text-align: center"><A NAME="a_006"></A>SELECTED
FINANCIAL DATA REFLECTING<BR>
THE 2024 REVERSE STOCK SPLIT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">2024 Reverse Stock Split</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">On July 17, 2024 we effected the 2024 Reverse Stock Split, a 1-for-200
reverse stock split of our Common Stock. The total number of outstanding shares of Common Stock was reduced from approximately 98,827,831
shares to approximately 493,268 shares. The par value per share of Common Stock remained unchanged. Our audited consolidated financial
statements included in our 2023 Annual Report, and the unaudited condensed consolidated financial statements included in our Quarterly
Report on Form&nbsp;10-Q for the period ended September 30, 2024, which are incorporated by reference into this prospectus, are presented
without giving effect to the 2024 Reverse Stock Split. Except where the context otherwise requires, share numbers in this prospectus reflect
the 1-for-200 2024&nbsp;Reverse Stock Split of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The following selected financial data has been derived from our
audited consolidated financial statements included in our 2023 Annual Report, as adjusted to reflect the 2024 Reverse Stock Split for
all periods presented. Our historical results are not indicative of the results that may be expected in the future and results of interim
periods are not indicative of the results for the entire year.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">As reported:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 12pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Years
    Ended <BR> December 31,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 12pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2023</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2022</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 12pt">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 12pt">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 12pt">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; text-align: left">Net loss from continuing operations</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">(41,762,479</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">(41,375,067</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss from discontinued operations, net of tax benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(5,070,707</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,487,130</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss attributable to Scorpius Holdings, Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(45,217,168</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(43,434,706</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss per share, basic and diluted &ndash; continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1.54</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1.60</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss per share, basic and diluted &ndash; discontinued operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.19</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.10</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss per share attributable to Scorpius Holdings, Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1.74</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1.70</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Weighted average common shares outstanding, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,046,594</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,606,326</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Common shares outstanding at year end</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,219,461</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,661,488</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  "></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif">As adjusted for 1-for-200 reverse stock split:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 12pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Years
    Ended <BR> December 31,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 12pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2023</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2022</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 12pt">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 12pt">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 12pt">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; text-align: left">Net loss from continuing operations</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">(41,762,479</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">(41,375,067</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss from discontinued operations, net of tax benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(5,070,707</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,487,130</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss attributable to Scorpius Holdings, Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(45,217,168</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(43,434,706</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss per share, basic and diluted &ndash; continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(320.68</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(323.16</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss per share, basic and diluted &ndash; discontinued operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(38.94</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(19.43</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss per share attributable to Scorpius Holdings, Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(347.20</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(339.25</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Weighted average common shares outstanding, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">130,232</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">128,031</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Common shares outstanding at year end</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">131,097</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">128,307</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif;   text-transform: uppercase; letter-spacing: 0.6pt; text-align: center"><A NAME="a_007"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Certain statements contained or incorporated by reference into this
prospectus may contain &ldquo;forward-looking statements&rdquo; within the meaning of the federal securities laws. Our forward-looking
statements include, but are not limited to, statements about us and our industry, as well as statements regarding our or our management
team&rsquo;s expectations, hopes, beliefs, intentions or strategies regarding the future. Additionally, any statements that refer to projections,
forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.
We intend the forward-looking statements to be covered by the safe harbor provisions of the federal securities laws. Words such as &ldquo;may,&rdquo;
&ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo;
&ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;future,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo;
&ldquo;estimates,&rdquo; and similar expressions, as well as statements in future tense, may identify forward-looking statements, but
the absence of these words does not mean that a statement is not forward-looking.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Forward-looking statements should not be read as a guarantee of
future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking
statements are based on information we have when those statements are made or management&rsquo;s good faith belief as of that time with
respect to future events and are subject to significant risks and uncertainties that could cause actual performance or results to differ
materially from those expressed in or suggested by the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">These statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity,
performance or achievement to differ materially from those expressed or implied by these forward-looking statements. We discuss in greater
detail, and incorporate by reference into this prospectus in their entirety, many of these risks and uncertainties under the heading &ldquo;<A HREF="#a_005">Risk Factors</A>&rdquo; contained in this prospectus and in the documents incorporated by reference herein. Moreover, we operate in a rapidly changing
and competitive environment. New risk factors emerge from time to time, and it is not possible for management to predict all such risk
factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Further, it is not possible to assess the effect of all risk factors
on our businesses or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those
contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking
statements as a prediction of actual results. In addition, we disclaim any obligation to correct or update any forward-looking statements
to reflect events or circumstances that occur after the date of this prospectus.</P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif;   text-transform: uppercase; letter-spacing: 0.6pt; text-align: center"><A NAME="a_008"></A>USE
OF PROCEEDS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We estimate that the net proceeds we will receive from the sale
of our securities in this Offering, after deducting underwriting discounts and commissions and estimated expenses payable by us, will
be approximately $6.3 million (or $7.3&nbsp;million if the representative exercises its option to purchase additional shares in full),
assuming no sale of Pre-Funded Warrants and assuming that the Investors holding the Secured Convertible Notes require that we use $2.5&nbsp;million
from the proceeds of this Offering to repay a portion of the Secured Convertible Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The Secured Convertible Notes provide that, while the Secured Convertible
Notes are outstanding, if we enter into a Subsequent Placement (which would include this Offering), each of the Investors shall have the
right, in their sole discretion, to require that we redeem all, or any portion, of the amount due under their Secured Convertible Note
in an amount not in excess of the Investor&rsquo;s pro rata amount of 25% of the gross proceeds of such Subsequent Placement. The Secured
Convertible Notes mature on the third anniversary of their date of issuance, or December&nbsp;6, 2027, unless prior thereto there is an
event of default, and bear interest at a rate of 9% per annum payable in cash on the first business day of each fiscal quarter beginning
January&nbsp;2, 2025. We used the proceeds from issuing the Secured Convertible Notes to repurchase certain pre-funded warrants held by
the Investors, to repay the November&nbsp;2024 Note held by one of the Investors, and for working capital and other general corporate
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We currently expect to use the net proceeds from this Offering,
after any required repayment of a portion of the Secured Convertible Notes, for working capital and other general corporate purposes.
The amounts and timing of these expenditures will depend on numerous factors, including the development of our current business initiatives.
As of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds from this Offering
and our management will have discretion and flexibility in applying the net proceeds of this Offering. An investor will not have the opportunity
to evaluate the economic, financial or other information on which we base our decisions on how to use the proceeds. We may use the proceeds
of this Offering for purposes with which you do not agree. Moreover, our management may use the net proceeds for corporate purposes that
may not result in our being profitable or increase our market value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">A $0.10 increase (decrease) in the assumed public offering price
of $0.34 per share would increase (decrease) the net proceeds to us from this Offering by approximately $2.0&nbsp;million, assuming the
number of shares offered by us, as set forth on the cover of this prospectus, remains the same and assuming no sale of Pre-Funded Warrants
and, after deducting underwriting discounts and commissions and estimated expenses payable by us. An increase (decrease) of 500,000 in
the number of shares offered by us in this Offering, would increase (decrease) the net proceeds to us from this Offering by approximately
$114,000, assuming the public offering price of $0.34 per share, remains the same and assuming no sale of Pre-Funded Warrants and, after
deducting underwriting discounts and commissions and estimated expenses payable by us. The information above is illustrative only and
will change based on the actual public offering price and other terms of this Offering determined at pricing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Based on our current projections, we believe the net proceeds of
this Offering will fund our operations through April&nbsp;2025 (or May&nbsp;2025 if the representative exercises its option to purchase
additional shares in full).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Pending our use of the net proceeds from this Offering, we intend
to invest the net proceeds in a variety of capital preservation investments, including short-term, investment-grade, interest-bearing
instruments and U.S. government securities.</P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif;   text-transform: uppercase; letter-spacing: 0.6pt; text-align: center"><A NAME="a_009"></A>CAPITALIZATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The following table sets forth our cash and our capitalization as
of September&nbsp;30, 2024:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">on an actual basis; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">on a pro forma basis, giving effect to (i) the issuance of 1,329,000&nbsp;shares of Common Stock upon
the exercise of pre-funded warrants; (ii) the issuance of the Secured Convertible Notes and warrants in December 2024 and the receipt
of net proceeds of approximately $3.3 million from such issuance and (iii) the repurchase of pre-funded warrants to purchase 8,500,000&nbsp;shares
of Common Stock from the gross proceeds received from the issuance of the Secured Convertible Notes and warrants in December 2024 ; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">on a pro forma as adjusted basis, giving effect to our issuance and sale of 29,411,764&nbsp;Shares based
on an assumed public offering price of $0.34 per share (which is the last reported sale price of our Common Stock on NYSE American on
December&nbsp;20, 2024) and assuming no exercise of the representative&rsquo;s over-allotment option and no sale of Pre-Funded Warrants,
after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The pro forma as adjusted information set forth in the table below
is illustrative only and will be adjusted based on the actual public offering price and other terms of this Offering as determined at
pricing. You should read the information in this table together with our consolidated financial statements and related notes and &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; in our Quarterly Report on Form 10-Q for the quarter ended
September&nbsp;30, 2024, incorporated by reference into this prospectus.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">September&nbsp;30, 2024</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Actual</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Pro
    Forma</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Pro
    Forma <BR> As Adjusted</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; font-size: 10pt; text-align: left; padding-left: 5.4pt">Cash and cash equivalents</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">4,559,334</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">7,774,057</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><SUP>(1)</SUP></TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">14,074,057</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 5.4pt">Convertible Note Payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,060,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,060,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,060,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 5.4pt">Secured Convertible Notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,050,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9,550,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 5.4pt">Stockholder&rsquo;s equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 13.5pt">Common stock, $0.0002 par value; 250,000,000 shares authorized; 3,539,268&nbsp;shares issued and outstanding, actual; 4,868,268&nbsp;shares issued and outstanding, pro forma; and 34,280,032&nbsp;shares issued and outstanding pro forma as adjusted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,974</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,274</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,156</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 5.4pt">Additional paid-in capital</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">306,485,190</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">297,652,890</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">306,447,007</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 5.4pt">Accumulated deficit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(277,777,368</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(277,777,645</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(277,777,645</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 5.4pt">Accumulated other comprehensive income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16,335</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16,335</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16,335</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 5.4pt">Total Stockholder&rsquo;s Equity- Scorpius Holdings, Inc.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">28,727,131</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">19,892,854</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">28,692,854</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 5.4pt">Non-Controlling Interest</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,182,805</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,182,805</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,182,805</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 5.4pt">Total Stockholder&rsquo;s Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">24,544,326</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">15,710,049</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">24,510,049</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt; line-height: 106%">Total Capitalization<SUP>(2)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">26,604,326</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">29,820,049</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">36,120,049</TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>(3)</SUP></TD></TR>
  </TABLE>
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; "><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD><FONT STYLE="font-size: 10pt">Cash does not take into account our net cash burn subsequent to September&nbsp;30, 2024. As of December&nbsp;20,
2024, our cash and cash equivalents and short-term investments were approximately $1.8 million.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD><FONT STYLE="font-size: 10pt">
The features of the December Warrants may result in a warrant derivative liability that we would record
in our financial statements. Accordingly, a portion of the net proceeds from such sale may be allocated to a derivative warrant liability
instead of equity. We have not yet finalized the accounting treatment for the issuance of the December Warrants and therefore at this
time cannot determine the extent of such liability, if any.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif;"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD><FONT STYLE="font-size: 10pt">
The features of the Secured Convertible Notes may result in a bifurcated derivative liability that we
would record in our financial statements. Accordingly, a portion of the net proceeds from such note may be allocated to an embedded derivative
liability rather than note payable. We have not yet finalized the accounting treatment for the issuance of the Secured Convertible Notes
and therefore at this time cannot determine the extent of such liability, if any.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt">A $0.10 increase or decrease in the assumed public offering price
of $0.34 per share (which is the last reported sale price of our Common Stock on NYSE American on December&nbsp;20, 2024), assuming no
sale of Pre-Funded Warrants, would increase or decrease the pro forma as adjusted amount of each of cash and cash equivalents, additional
paid-in capital, total stockholders&rsquo; equity and total capitalization by approximately $2.0&nbsp;million, assuming that the number
of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us and assuming exercise of the representative&rsquo;s over-allotment
option and no sale of Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0">An increase or decrease of 500,000 shares in the number of Shares
offered by us, as set forth on the cover page of this prospectus, would increase or decrease the pro forma as adjusted amount of each
of cash and cash equivalents, additional paid-in capital, total stockholders&rsquo; equity and total capitalization by approximately $114,000,
assuming no change in the assumed public offering price per share and after deducting the estimated underwriting discounts and commissions
and estimated offering expenses payable by us and assuming no exercise of the representative&rsquo;s over-allotment option and no sale
of Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The table above is based on 3,539,268 shares of our Common Stock
outstanding as of September&nbsp;30, 2024; assumes no exercise of the representative&rsquo;s over-allotment option, no sale of Pre-Funded
Warrants, and no issuance of Representative&rsquo;s Warrants in this Offering; and excludes as of September&nbsp;30, 2024 the following:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">30,738 shares of Common Stock issuable upon exercise of stock options outstanding and expected to vest
as of September&nbsp;30, 2024, at a weighted-average exercise price of $678.21 per share;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">11,329,000 shares of Common Stock issuable upon exercise of pre-funded warrants outstanding, at an exercise
price of $0.0002 per share (1,500,000 after adjustment to reflect the pro form adjustments set forth above);</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">299,112 shares of Common Stock issuable upon exercise of Common Warrants outstanding as of September
30, 2024, at an exercise price of $24.00 per share;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">103,908 shares of Common Stock issuable upon conversion in full (including accrued interest thereon
calculated as of the date of maturity) of the Restated Note (the conversion of which is subject to both Elusys Holdings&rsquo; election
and any required approval of NYSE American of such share issuance); </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Up to 47,396,667 shares of Common Stock issuable upon conversion in full (including make-whole amounts)
of the Secured Convertible Notes and upon exercise of the December Warrants; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">156,269 shares of our Common Stock that are available for future issuance under our stock incentive
plans or shares that will become available under our stock incentive plans (after giving effect to the amendment to our 2018 Equity Incentive
Plan approved by our stockholders on July 15, 2024 to increase by 150,000 the number of shares available for grant under our 2018 Equity
Incentive Plan).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif;   text-transform: uppercase; letter-spacing: 0.6pt; text-align: center"><A NAME="a_010"></A>DESCRIPTION
OF SECURITIES WE ARE OFFERING</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We are offering up to 29,411,764 Shares, or Pre-Funded Warrants
in lieu of Shares. For each Pre-Funded Warrant we sell, the number of shares of Common Stock we are offering will be decreased on a one-for-one
basis. We are also registering the shares of Common Stock issuable from time to time upon exercise of the Pre-Funded Warrants offered
hereby.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">General</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The following is a description of the material terms of our Common
Stock. This is a summary only and does not purport to be complete. It is subject to and qualified in its entirety by reference to our
Third Amended and Restated Certificate of Incorporation, as amended (the &ldquo;Certificate of Incorporation&rdquo;) and our Second Amended
and Restated Bylaws (the &ldquo;Bylaws&rdquo;), each of which is filed as an exhibit to the registration statement of which this prospectus
forms a part. We encourage you to read the Certificate of Incorporation, the Bylaws and the applicable provisions of the Delaware General
Corporation Law, for additional information.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Description of Common Stock</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Authorized Shares of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We currently have authorized 250,000,000 shares of Common Stock.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Voting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The holders of our Common Stock are entitled to one vote for each
share held of record on all matters submitted to a vote of the stockholders, including the election of directors, and do not have cumulative
voting rights.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Dividends</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Subject to preferences that may be applicable to any then outstanding
preferred stock, the holders of Common Stock are entitled to receive dividends, if any, as may be declared from time to time by our board
of directors out of legally available funds.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Liquidation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">In the event of our liquidation, dissolution or winding up, holders
of our Common Stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment
of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any then
outstanding shares of preferred stock.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Rights and Preferences</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The holders of our Common Stock have no preemptive, conversion or
subscription rights, and there are no redemption or sinking fund provisions applicable to our Common Stock. The rights, preferences and
privileges of the holders of our Common Stock are subject to, and may be adversely affected by, the rights of the holders of shares of
any series of our preferred stock that we may designate and issue in the future.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  "></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif">Stockholder Rights Plan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">On March 11, 2018, our board of directors declared a dividend of
one common share purchase right (a &ldquo;Right&rdquo;) for each outstanding share of our Common Stock, which was amended by Amendment
No. 1 thereto on March 8, 2019 , by Amendment No. 2 thereto on March 10, 2020, by Amendment No. 3 thereto on March 8, 2021, by Amendment
No. 4 on March 11, 2022, by Amendment No. 5 thereto on March 11, 2023 , by Amendment No. 6 thereto on December 11, 2023 and by Amendment
No. 7 on March 11, 2024 to extend the expiration date of the stockholder&rsquo;s rights plan to March 11, 2025. The dividend was initially
paid on March 23, 2018 (the &ldquo;Record Date&rdquo;) to the stockholders of record at the close of business on that date. Each Right
initially entitles the registered holder to purchase from us one share of Common Stock at a price of $14.00 per share of Common Stock
(the &ldquo;Purchase Price&rdquo;), subject to adjustment. The description and terms of the Rights are set forth in a Rights Agreement,
dated as of March 11, 2018, as amended by Amendment No. 1 thereto dated March 8, 2019, Amendment No. 2 thereto dated March 10, 2020, Amendment
No. 3 thereto dated March 8, 2021, Amendment No. 4 thereto dated March 11, 2022, Amendment No. 5 thereto dated March 11, 2023, Amendment
No. 6 thereto dated December 11, 2023 and Amendment No. 7 thereto dated March 11, 2024 as the same may be further amended from time to
time (the &ldquo;Rights Agreement&rdquo;), between the Company and Continental Stock Transfer &amp; Trust Company, as Rights Agent (the
&ldquo;Rights Agent&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The Rights are designed to assure that all of our stockholders receive
fair and equal treatment in the event of a hostile takeover of the Company, to guard against two-tier or partial tender offers, open market
accumulations and other tactics designed to gain control of the Company without paying all stockholders a fair price, and to enhance the
board of director&rsquo;s ability to negotiate with any prospective acquiror. Until the earlier to occur of (i) 10 business days following
a public announcement that a person or group of affiliated or associated persons has become an Acquiring Person (as defined below) or
(ii) 10 business days (or such later date as may be determined by action of the board of directors prior to such time as any person or
group of affiliated or associated persons becomes an Acquiring Person) following the commencement of, or public announcement of an intention
to make, a tender or exchange offer the consummation of which would result in any person or group of affiliated or associated persons
becoming an Acquiring Person (the earlier of such dates being called the &ldquo;Distribution Date&rdquo;), the Rights will be evidenced,
with respect to certificates representing Common Stock (or book entry shares of Common Stock) outstanding as of the Record Date, by such
certificates (or such book entry shares) together with a copy of a summary of the Rights (the &ldquo;Summary of Rights&rdquo;). Except
in certain situations, a person or group of affiliated or associated persons becomes an &ldquo;Acquiring Person&rdquo; upon acquiring
beneficial ownership of 20% or more of the outstanding shares of Common Stock. Certain synthetic interests in securities created by derivative
positions &ndash; whether or not such interests are considered to be ownership of the underlying Common Stock or are reportable for purposes
of Regulation 13D of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) &ndash; are treated as beneficial
ownership of the number of shares of Common Stock equivalent to the economic exposure created by the derivative security, to the extent
actual shares of Common Stock are directly or indirectly beneficially owned by a counterparty to such derivative security. Amendment No.
6 exempted Mr. Wolf and his affiliated entity from being an Acquiring Person under certain specified circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The Rights Agreement provides that, until the Distribution Date
(or earlier expiration of the Rights), the Rights will be transferred with and only with the Common Stock. Until the Distribution Date
(or earlier expiration of the Rights), new Common Stock certificates issued after the Record Date upon transfer or new issuances of Common
Stock will contain a notation incorporating the Rights Agreement by reference. Until the Distribution Date (or earlier expiration of the
Rights), the surrender for transfer of any certificates for shares of Common Stock (or book entry shares of Common Stock) outstanding
as of the Record Date, even without such notation or a copy of the Summary of Rights, will also constitute the transfer of the Rights
associated with the shares of Common Stock represented thereby. As soon as practicable following the Distribution Date, separate certificates
evidencing the Rights (&ldquo;Right Certificates&rdquo;) will be mailed to holders of record of the Common Stock as of the close of business
on the Distribution Date and such separate Right Certificates alone will evidence the Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The Rights are not exercisable until the Distribution Date. The
Rights will expire at the close of business on March 11, 2025, unless the Rights are earlier redeemed or exchanged by the Company as described
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The Purchase Price payable, and the number of shares of Common Stock
(or cash, other assets, debt securities of the Company, or any combination thereof equivalent in value thereto) issuable, upon exercise
of the Rights is subject to adjustment from time to time to prevent dilution (i) in the event of a stock dividend on, or a subdivision,
combination or reclassification of, the Common Stock, (ii) upon the grant to holders of the Common Stock of certain rights or warrants
to subscribe for or purchase Common Stock at a price, or securities convertible into Common Stock with a conversion price, less than the
then-current market price of the Common Stock or (iii) upon the distribution to holders of the Common Stock of evidences of indebtedness
or assets (excluding regular periodic cash dividends or dividends payable in Common Stock) or of subscription rights or warrants (other
than those referred to above).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The number of outstanding Rights is subject to adjustment in the
event of a stock dividend on the Common Stock payable in shares of Common Stock or subdivisions, consolidations or combinations of the
Common Stock occurring, in any such case, prior to the Distribution Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">In the event that any person or group of affiliated or associated
persons becomes an Acquiring Person, each holder of a Right, other than Rights beneficially owned by the Acquiring Person (which will
thereupon become void), will thereafter have the right to receive upon exercise of a Right that number of shares of Common Stock (or cash,
property debt securities of the Company, or any combination thereof) having a market value of two times the exercise price of the Right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">In the event that, after a person or group has become an Acquiring
Person, the Company is acquired in a merger or other business combination transaction or 50% or more of its consolidated assets or earning
power are sold, proper provisions will be made so that each holder of a Right (other than Rights beneficially owned by an Acquiring Person
which will have become void) will thereafter have the right to receive upon the exercise of a Right that number of shares of Common Stock
of the person with whom the Company has engaged in the foregoing transaction (or its parent) that at the time of such transaction have
a market value of two times the exercise price of the Right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">At any time after any person or group becomes an Acquiring Person
and prior to the earlier of one of the events described in the previous paragraph or the acquisition by such Acquiring Person of 50% or
more of the outstanding shares of Common Stock, the board of directors may exchange the Rights (other than Rights owned by such Acquiring
Person which will have become void), in whole or in part, for shares of Common Stock (or cash, other assets, debt securities of the Company,
or any combination thereof with an aggregate value equal to such shares) at an exchange ratio of one share of Common Stock (or cash, other
assets, debt securities of the Company, or any combination thereof equivalent in value thereto) per Right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">With certain exceptions, no adjustment in the Purchase Price will
be required until cumulative adjustments require an adjustment of at least 1% in such Purchase Price. No fractional shares of Common Stock
will be issued, and in lieu thereof a cash payment will be made based on then current market price of the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">At any time prior to the time an Acquiring Person becomes such,
the Board may redeem the Rights in whole, but not in part, at a price of $0.001 per Right (the &ldquo;Redemption Price&rdquo;) payable,
at the option of the Company, in cash, shares of Common Stock or such other form of consideration as the board of directors shall determine.
The redemption of the Rights may be made effective at such time, on such basis and with such conditions as the board of directors in its
sole discretion may establish. Immediately upon any redemption of the Rights, the right to exercise the Rights will terminate and the
only right of the holders of Rights will be to receive the Redemption Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">For so long as the Rights are then redeemable, the Company may,
except with respect to the Redemption Price, amend the Rights Agreement in any manner. After the Rights are no longer redeemable, the
Company may, except with respect to the Redemption Price, amend the Rights Agreement in any manner that does not adversely affect the
interests of holders of the Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Until a Right is exercised or exchanged, the holder thereof, as
such, will have no rights as a stockholder of the Company, including, without limitation, the right to vote or to receive dividends. For
more detailed information, please see the Rights Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  "></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif">Potential Anti-Takeover Effects</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Certain provisions set forth in our Certificate of Incorporation
and Bylaws, our Rights Agreement and in Delaware law, which are summarized below, may be deemed to have an anti-takeover effect and may
delay, deter or prevent a tender offer or takeover attempt that a stockholder might consider to be in its best interests, including attempts
that might result in a premium being paid over the market price for the shares held by stockholders.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Proposals of Business and Nominations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Our Bylaws generally regulate proposals of business and nominations
for election of directors by stockholders. In general, Section 2.14 requires stockholders intending to submit proposals or nominations
at a stockholders meeting to provide the Company with advance notice thereof, including information regarding the stockholder proposing
the business or nomination as well as information regarding the proposed business or nominee. Section 2.14 provides a time period during
which business or nominations must be provided to the Company that will create a predictable window for the submission of such notices,
eliminating the risk that the Company finds a meeting will be contested after printing its proxy materials for an uncontested election
and providing the Company with a reasonable opportunity to respond to nominations and proposals by stockholders.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Board Vacancies</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Our Bylaws generally provide that only the board of directors (and
not the stockholders) may fill vacancies and newly created directorships.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Special Meeting of Stockholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Our Bylaws generally provide that only the board of directors may
call a special meeting of stockholders and that the board of directors may postpone, reschedule or cancel any special meeting of stockholders
that was previously scheduled by the board of directors.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Stockholder Rights Plan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The Rights issued pursuant to the Rights Agreement, if not redeemed
or suspended, could work to dilute the stock ownership of a potential hostile acquirer, likely preventing acquisitions that have not been
approved by our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">While the foregoing provisions of our Certificate of Incorporation,
Bylaws, Rights Agreement plan and Delaware law may have an anti-takeover effect, these provisions are intended to enhance the likelihood
of continuity and stability in the composition of the Board of directors and in the policies formulated by the board of directors and
to discourage certain types of transactions that may involve an actual or threatened change of control. In that regard, these provisions
are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain
tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers
for our shares and, as a consequence, they also may inhibit fluctuations in the market price of our Common Stock that could result from
actual or rumored takeover attempts. Such provisions also may have the effect of preventing changes in our management.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Exclusive Forum</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The exclusive forum for adjudication of disputes provision contained
in our Bylaws limits the forum to the Delaware Court of Chancery for certain actions against us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Our Bylaws provide that, unless we consent to the selection of an
alternative forum, the Court of Chancery of the State of Delaware is the exclusive forum for (i) any derivative action or proceeding brought
on behalf of us, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, or other employees
to us or our stockholders, (iii) any action arising pursuant to any provision of the Delaware General Corporation Law, or (iv) any action
asserting a claim governed by the internal affairs doctrine, except, in each case for claims arising under the Securities Act, the Exchange
Act, or other federal securities laws for which there is exclusive federal or concurrent federal and state jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We believe limiting state law-based claims to Delaware will provide
the most appropriate outcomes as the risk of another forum misapplying Delaware law is avoided, Delaware courts have a well-developed
body of case law and limiting the forum will preclude costly and duplicative litigation and avoids the risk of inconsistent outcomes.
Additionally, Delaware Chancery Courts can typically resolve disputes on an accelerated schedule when compared to other forums. While
we believe limiting the forum for state law-based claims is a benefit, stockholders could be inconvenienced by not being able to bring
certain actions in another forum they find favorable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Delaware Anti-Takeover Statute</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We are subject to Section 203 of the DGCL. Subject to certain exceptions,
Section 203 prevents a publicly held Delaware corporation from engaging in a &ldquo;business combination&rdquo; with any &ldquo;interested
stockholder&rdquo; for three years following the date that the person became an interested stockholder, unless the interested stockholder
attained such status with the approval of our Board of Directors or unless the business combination is approved in a prescribed manner.
A &ldquo;business combination&rdquo; includes, among other things, a merger or consolidation involving us and the &ldquo;interested stockholder&rdquo;
and the sale of more than 10% of our assets. In general, an &ldquo;interested stockholder&rdquo; is any entity or person beneficially
owning 15% or more of our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity
or person.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Listing of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">On June 14, 2024, we received notice from the NYSE Regulation that
it had suspended trading of our Common Stock on NYSE American and determined to commence proceedings to delist our Common Stock from NYSE
American as a result of its determination that we were no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American
Company Guide due to the low selling price of our Common Stock. Our Common Stock began to be quoted on the OTC Markets system on June
17, 2024. On July 17, 2024, we effected the 2024 Reverse Stock Split to increase the selling price of our Common Stock in order to regain
compliance with the requirements and policies of NYSE American. On July 29, 2024, NYSE American notified us that it had withdrawn its
delisting determination and our Common Stock resumed trading on NYSE American on Friday, August 2, 2024, under the symbol &ldquo;SCPX.&rdquo;
However, there can be no assurance that the market price of our Common Stock following the 2024 Reverse Stock Split will remain at a level
that will be sufficient to meet any requirements and policies of NYSE American or that our Common Stock will remain listed on NYSE American.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Transfer Agent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The transfer agent and registrar for our Common Stock is Continental
Stock Transfer &amp; Trust Company. They are located at 1 State Street, 30th floor, New York, New York 10004. Their telephone number is
(212) 509-4000.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Pre-Funded Warrants to be Issued in this Offering</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The following summary of certain terms and provisions of the Pre-Funded
Warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the Pre-Funded
Warrant, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors
should carefully review the terms and provisions of the form of Pre-Funded Warrant for a complete description of the terms and conditions
of the Pre-Funded Warrants.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  "></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif">Duration and Exercise Price</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Each Pre-Funded Warrant offered hereby will have an initial exercise
price per share equal to $0.0002. The Pre-Funded Warrants will be immediately exercisable and will expire when exercised in full. The
exercise price and number of shares of Common Stock issuable upon exercise is subject to appropriate adjustment in the event of share
dividends, share splits, reorganizations or similar events affecting our shares of Common Stock and the exercise price.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Exercisability</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The Pre-Funded Warrants will be exercisable, at the option of each
holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares
of Common Stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its
affiliates) may not exercise any portion of the Pre-Funded Warrant to the extent that the holder would own more than 4.99%/9.99% of the
outstanding shares of our Common Stock immediately after exercise, except that upon at least 61 days&rsquo; prior notice from the holder
to us, the holder may increase the amount of beneficial ownership of outstanding shares after exercising the holder&rsquo;s Pre-Funded
Warrants up to 9.99% of the number of our shares of Common Stock outstanding immediately after giving effect to the exercise, as such
percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. Purchasers of Pre-Funded Warrants in this
Offering may also elect prior to the issuance of the Pre-Funded Warrants to have the initial exercise limitation set at 9.99% of our outstanding
shares of Common Stock.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Cashless Exercise</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">If, at the time a holder exercises its Pre-Funded Warrants, a registration
statement registering the issuance of the shares of Common Stock underlying the Pre-Funded Warrants under the Securities Act of 1933,
as amended (the &ldquo;Securities Act&rdquo;) is not then effective or available for the issuance of such shares, then in lieu of making
the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may
elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according
to a formula set forth in the Pre-Funded Warrants.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Fractional Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">No fractional shares of Common Stock will be issued upon the exercise
of the Pre-Funded Warrants. Rather, the number of shares of Common Stock to be issued will, at our election, either be rounded up to the
next whole share or we will pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by
the exercise price.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Transferability</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Subject to applicable laws, a Pre-Funded Warrant may be transferred
at the option of the holder upon surrender of the Pre-Funded Warrant to us together with the appropriate instruments of transfer and funds
sufficient to pay any transfer taxes payable upon such transfer.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Trading Market</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">There is no trading market available for the Pre-Funded Warrants
on any securities exchange or nationally recognized trading system, and we do not expect a trading market to develop. We do not intend
to list the Pre-Funded Warrants on any securities exchange or nationally recognized trading market. Without a trading market, the liquidity
of the Pre-Funded Warrants will be extremely limited.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  "></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif">Right as a Stockholder</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Except as otherwise provided in the Pre-Funded Warrants or by virtue
of such holder&rsquo;s ownership of Common Stock, the holders of the Pre-Funded Warrants do not have the rights or privileges of holders
of our Common Stock, including any voting rights, until they exercise their Pre-Funded Warrants. The Pre-Funded Warrants will provide
that holders have the right to participate in distributions or dividends paid on Common Stock.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Fundamental Transaction</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">In the event of a fundamental transaction, as described in the Pre-Funded
Warrants and generally including (i)&nbsp;our merger or consolidation with or into another person, (ii)&nbsp;the sale, lease, license,
assignment, transfer, conveyance or other disposition of all or substantially all of our assets, (iii)&nbsp;any purchase offer, tender
offer or exchange offer pursuant to which holders of our Common Stock are permitted to sell, tender or exchange their shares for other
securities, cash or property and has been accepted by the holders of 50% or more of our outstanding Common Stock or 50% or more of the
voting power of our common equity, (iv)&nbsp;any reclassification, reorganization or recapitalization of our shares of Common Stock or
any compulsory share exchange or (v)&nbsp;any stock or share purchase agreement or other business combination with another person or group
of persons whereby such other person or group acquires 50% or more of our outstanding shares of Common Stock or 50% or more of the voting
power of our common equity, the holders of the Pre-Funded Warrants will be entitled to receive upon exercise of the Pre-Funded Warrants
the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants
immediately prior to such fundamental transaction on a net exercise basis.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Description of Representative&rsquo;s Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">If the gross proceeds from this Offering are at least $11 million,
then we have agreed to issued to the representative warrants to purchase such number of shares of Common Stock equal to 5% of the aggregate
number of shares of Common Stock and Pre-Funded Warrants sold in this Offering. The Representative&rsquo;s Warrants will be exercisable
at any time, and from time to time, in whole or in part, during the four and one-half year period commencing 180 days from commencement
of sales of securities in this Offering at a per share price equal to 125% of the public offering price per share of Common Stock in the
Offering. The Representative&rsquo;s Warrants will provide for customary anti-dilution provisions (the exercise price and number of shares
of Common Stock issuable upon exercise is subject to appropriate adjustment in the event of share dividends, share splits, reorganizations
or similar events affecting our shares of Common Stock and the exercise price) consistent with FINRA Rule 5110, and further, the number
of shares underlying the Representative&rsquo;s Warrants shall be reduced if necessary to comply with FINRA rules are regulations.</P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif;   text-transform: uppercase; letter-spacing: 0.6pt; text-align: center"><A NAME="a_011"></A>MATERIAL
UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The following discussion describes the material U.S. federal income
tax consequences of the acquisition, ownership and disposition of the Shares and Pre-Funded Warrants acquired in this Offering. This discussion
is based on the current provisions of the Internal Revenue Code of 1986, as amended, referred to as the Code, existing and proposed U.S.
Treasury regulations promulgated thereunder, and administrative rulings and court decisions in effect as of the date hereof, all of which
are subject to change at any time, possibly with retroactive effect. No ruling has been or will be sought from the Internal Revenue Service,
or IRS, with respect to the matters discussed below, and there can be no assurance the IRS will not take a contrary position regarding
the tax consequences of the acquisition, ownership or disposition of the Shares or Pre-Funded Warrants, or that any such contrary position
would not be sustained by a court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We assume in this discussion that the Shares and Pre-Funded Warrants
will be held as capital assets (generally, property held for investment). This discussion does not address all aspects of U.S. federal
income taxes, does not discuss the potential application of the Medicare contribution tax or the alternative minimum tax and does not
address state or local taxes or U.S. federal gift and estate tax laws, except as specifically provided below with respect to non-U.S.
holders, or any non-U.S. tax consequences that may be relevant to holders in light of their particular circumstances. This discussion
also does not address the special tax rules applicable to particular holders, such as:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">persons who acquired our Common Stock or Pre-Funded Warrants as compensation for services;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">traders in securities that elect to use a mark-to-market method of accounting for their securities holdings;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">persons that own, or are deemed to own, more than 5% of our Common Stock (except to the extent specifically
set forth below);</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">persons required for U.S. federal income tax purposes to conform the timing of income accruals to their
financial statements under Section 451(b) of the Code (except to the extent specifically set forth below);</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">persons for whom our Common Stock constitutes &ldquo;qualified small business stock&rdquo; within the
meaning of Section 1202 of the Code or &ldquo;Section 1244 stock&rdquo; for purposes of Section 1244 of the Code;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">persons deemed to sell our Common Stock or Pre-Funded Warrants under the constructive sale provisions
of the Code;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">banks or other financial institutions;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">brokers or dealers in securities or currencies;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">tax-exempt organizations or tax-qualified retirement plans;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">pension plans;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">regulated investment companies or real estate investment trusts;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">persons that hold the Common Stock or Pre-Funded Warrants as part of a straddle, hedge, conversion transaction,
synthetic security or other integrated investment;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">insurance companies;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">controlled foreign corporations, passive foreign investment companies, or corporations that accumulate
earnings to avoid U.S. federal income tax; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">certain U.S. expatriates, former citizens, or long-term residents of the United States.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">In addition, this discussion does not address the tax treatment
of partnerships (including any entity or arrangement classified as a partnership for U.S. federal income tax purposes) or other pass-through
entities or persons who hold shares of Common Stock or Pre-Funded Warrants through such partnerships or other entities which are pass-through
entities for U.S. federal income tax purposes. If such a partnership or other pass-through entity holds shares of Common Stock or Pre-Funded
Warrants, the treatment of a partner in such partnership or investor in such other pass-through entity generally will depend on the status
of the partner or investor and upon the activities of the partnership or other pass-through entity. A partner in such a partnership and
an investor in such other pass-through entity that will hold shares of Common Stock or Pre-Funded Warrants should consult his, her or
its own tax advisor regarding the tax consequences of the ownership and disposition of shares of Common Stock or Pre-Funded Warrants through
such partnership or other pass-through entity, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>This discussion of U.S. federal income tax considerations is
for general information purposes only and is not tax advice. Prospective investors should consult their own tax advisors regarding the
U.S. federal, state, local and non-U.S. income and other tax considerations of acquiring, holding and disposing of our Common Stock, and
Pre-Funded Warrants.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">For the purposes of this discussion, a &ldquo;U.S. Holder&rdquo;
means a beneficial owner of shares of Common Stock or Pre-Funded Warrants that is for U.S. federal income tax purposes (a) an individual
citizen or resident of the United States, (b) a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes),
created or organized in or under the laws of the United States, any state thereof or the District of Columbia, (c) an estate the income
of which is subject to U.S. federal income taxation regardless of its source, or (d) a trust if it (1) is subject to the primary supervision
of a court within the United States and one or more U.S. persons (within the meaning of Section 7701(a)(30) of the Code) has the authority
to control all substantial decisions of the trust or (2) has a valid election in effect under applicable U.S. Treasury regulations to
be treated as a domestic trust. A &ldquo;Non-U.S. Holder&rdquo; is, for U.S. federal income tax purposes, a beneficial owner of shares
of Common Stock or, Pre-Funded Warrants that is not a U.S. Holder or a partnership for U.S. federal income tax purposes.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Potential Acceleration of Income</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Under tax legislation signed into law in December 2017 commonly
known as the Tax Cuts and Jobs Act of 2017, U.S. Holders that use an accrual method of accounting for tax purposes and have certain financial
statements generally will be required to include certain amounts in income no later than the time such amounts are taken into account
as revenue in such financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">In addition, under the Inflation Reduction Act signed into law on
August 16, 2022, certain large corporations (generally, corporations reporting at least $1 billion average adjusted pre-tax net income
on their consolidated financial statements) are potentially subject to a 15% alternative minimum tax on the &ldquo;adjusted financial
statement income&rdquo; of such large corporations for tax years beginning after December 31, 2022. The U.S. Treasury Department, the
IRS, and other standard-setting bodies are expected to issue guidance on how the alternative minimum tax provisions of the Inflation Reduction
Act will be applied or otherwise administered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The application of these rules thus may require the accrual of income
earlier than would be the case under the general tax rules described below, although the precise application of these rules is unclear
at this time. U.S. Holders that use an accrual method of accounting should consult with their tax advisors regarding the potential applicability
of this legislation to their particular situation.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Treatment of Pre-Funded Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Although it is not entirely free from doubt, a pre-funded warrant
should be treated as a share of Common Stock for U.S. federal income tax purposes and a holder of Pre-Funded Warrants should generally
be taxed in the same manner as a holder of Common Stock, as described below. Accordingly, no gain or loss should be recognized upon the
exercise of a Pre-Funded Warrant and, upon exercise, the holding period of a Pre-Funded Warrant should carry over to the share of Common
Stock received. Similarly, the tax basis of the Pre-Funded Warrant should carry over to the share of Common Stock received upon exercise,
increased by the exercise price of $0.0002 per share. Each holder should consult his, her or its own tax advisor regarding the risks associated
with the acquisition of Pre-Funded Warrants pursuant to this Offering (including potential alternative characterizations). The balance
of this discussion generally assumes that the characterization described above is respected for U.S. federal income tax purposes.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  "></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif">Tax Considerations Applicable to U.S. Holders</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Distributions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">As discussed above, we currently anticipate that we will retain
future earnings, if any, to finance the growth and development of our business and do not intend to pay cash dividends in respect of shares
of Common Stock in the foreseeable future. In the event that we do make distributions on our Common Stock to a U.S. Holder, those distributions
generally will constitute dividends for U.S. tax purposes to the extent paid out of our current or accumulated earnings and profits (as
determined under U.S. federal income tax principles). Distributions in excess of our current and accumulated earnings and profits will
constitute a return of capital that is applied against and reduces, but not below zero, a U.S. Holder&rsquo;s adjusted tax basis in our
Common Stock. Any remaining excess will be treated as gain realized on the sale or exchange of shares of Common Stock as described below
under the section titled &ldquo;&mdash;Disposition of Common Stock or Pre-Funded Warrants.&rdquo;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Certain Adjustments to Pre-Funded Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The number of shares of Common Stock issued upon the exercise of
the Pre-Funded Warrants and the exercise price of Pre-Funded Warrants are subject to adjustment in certain circumstances. Adjustments
(or failure to make adjustments) that have the effect of increasing a U.S. Holder&rsquo;s proportionate interest in our assets or earnings
and profits may, in some circumstances, result in a constructive distribution to the U.S. Holder. Adjustments to the conversion rate made
pursuant to a bona fide reasonable adjustment formula which has the effect of preventing the dilution of the interest of the holders of
Pre-Funded Warrants generally should not be deemed to result in a constructive distribution. If an adjustment is made that does not qualify
as being made pursuant to a bona fide reasonable adjustment formula, a U.S. Holder of Pre-Funded Warrants may be deemed to have received
a constructive distribution from us, even though such U.S. Holder has not received any cash or property as a result of such adjustment.
The tax consequences of the receipt of a distribution from us are described above under &ldquo;Distributions.&rdquo;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Disposition of Common Stock or Pre-Funded Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Upon a sale or other taxable disposition (other than a redemption
treated as a distribution, which will be taxed as described above under &ldquo;Distributions&rdquo;) of shares of Common Stock or Pre-Funded
Warrants, a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between the amount realized
and the U.S. Holder&rsquo;s adjusted tax basis in the Common Stock or Pre-Funded Warrants sold. Capital gain or loss will constitute long-term
capital gain or loss if the U.S. Holder&rsquo;s holding period for the Common Stock or Pre-Funded Warrants exceeds one year. The deductibility
of capital losses is subject to certain limitations. U.S. Holders who recognize losses with respect to a disposition of shares of Common
Stock or Pre-Funded Warrants should consult their own tax advisors regarding the tax treatment of such losses.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Information Reporting and Backup Reporting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Information reporting requirements generally will apply to payments
of distributions (including constructive distributions) on the Common Stock and Pre-Funded Warrants and to the proceeds of a sale or other
disposition of Common Stock and Pre-Funded Warrants paid by us to a U.S. Holder unless such U.S. Holder is an exempt recipient, such as
a corporation. Backup withholding will apply to those payments if the U.S. Holder fails to provide the holder&rsquo;s taxpayer identification
number, or certification of exempt status, or if the holder otherwise fails to comply with applicable requirements to establish an exemption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Backup withholding is not an additional tax. Rather, any amounts
withheld under the backup withholding rules will be allowed as a refund or a credit against the U.S. Holder&rsquo;s U.S. federal income
tax liability provided the required information is timely furnished to the IRS. U.S. Holders should consult their own tax advisors regarding
their qualification for exemption from information reporting and backup withholding and the procedure for obtaining such exemption.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Tax Considerations Applicable to Non-U.S. Holders</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Certain Adjustments to Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">As described under &ldquo;&mdash;U.S. Holders&mdash;Certain Adjustments
to Pre-Funded Warrants,&rdquo; an adjustment to the Pre-Funded Warrants could result in a constructive distribution to a Non-U.S. Holder,
which would be treated as described under &ldquo;Distributions&rdquo; below. Any resulting withholding tax attributable to deemed dividends
would be collected from other amounts payable or distributable to the Non-U.S. Holder. Non-U.S. Holders should consult their tax advisors
regarding the proper treatment of any adjustments to the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">In addition, regulations governing &ldquo;dividend equivalents&rdquo;
under Section 871(m) of the Code may apply to the Pre-Funded Warrants. Under those regulations, an implicit or explicit payment under
Pre-Funded Warrants that references a dividend distribution on our Common Stock would possibly be taxable to a Non-U.S. Holder as described
under &ldquo;Distributions&rdquo; below. Such dividend equivalent amount would be taxable and subject to withholding whether or not there
is actual payment of cash or other property, and the Company may satisfy any withholding obligations it has in respect of the Pre-Funded
Warrants by withholding from other amounts due to the Non-U.S. Holder. Non-U.S. Holders are encouraged to consult their own tax advisors
regarding the application of Section 871(m) of the Code to the Pre-Funded Warrants.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Distributions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">As discussed above, we currently anticipate that we will retain
future earnings, if any, to finance the growth and development of our business and do not intend to pay cash dividends in respect of our
Common Stock in the foreseeable future. In the event that we do make distributions on our Common Stock to a Non-U.S. Holder, those distributions
generally will constitute dividends for U.S. federal income tax purposes as described in &ldquo;&mdash;U.S. Holders&mdash;Distributions.&rdquo;
To the extent those distributions do not constitute dividends for U.S. federal income tax purposes (i.e., the amount of such distributions
exceeds both our current and our accumulated earnings and profits), they will constitute a return of capital and will first reduce a Non-U.S.
Holder&rsquo;s basis in our Common Stock (determined separately with respect to each share of Common Stock), but not below zero, and then
will be treated as gain from the sale of that share of Common Stock as described below under the section titled &ldquo;&mdash;Disposition
of Common Stock or Pre-Funded Warrants.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Any distribution (including constructive distributions) on shares
of Common Stock that is treated as a dividend paid to a Non-U.S. Holder that is not effectively connected with the holder&rsquo;s conduct
of a trade or business in the United States will generally be subject to withholding tax at a 30% rate or such lower rate as may be specified
by an applicable income tax treaty between the United States and the Non-U.S. Holder&rsquo;s country of residence. To obtain a reduced
rate of withholding under a treaty, a Non-U.S. Holder generally will be required to provide the applicable withholding agent with a properly
executed IRS Form W-8BEN, IRS Form W-8BEN-E or other appropriate form, certifying the Non-U.S. Holder&rsquo;s entitlement to benefits
under that treaty. Such form must be provided prior to the payment of dividends and must be updated periodically. If a Non-U.S. Holder
holds stock through a financial institution or other agent acting on the holder&rsquo;s behalf, the holder will be required to provide
appropriate documentation to such agent. The holder&rsquo;s agent may then be required to provide certification to the applicable withholding
agent, either directly or through other intermediaries. If you are eligible for a reduced rate holding tax under an income tax treaty,
you should consult with your own tax advisor to determine if you are able to obtain a refund or credit of any excess amounts withheld
by timely filing an appropriate claim for a refund with the IRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We generally are not required to withhold tax on dividends paid
(or constructive dividends deemed paid) to a Non-U.S. Holder that are effectively connected with the holder&rsquo;s conduct of a trade
or business within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment
or fixed base that the holder maintains in the United States) if a properly executed IRS Form W-8ECI, stating that the dividends are so
connected, is furnished to us (or, if stock is held through a financial institution or other agent, to the applicable withholding agent).
In general, such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular tax rates
applicable to U.S. persons. A corporate Non-U.S. Holder receiving effectively connected dividends may also be subject to an additional
&ldquo;branch profits tax,&rdquo; which is imposed, under certain circumstances, at a rate of 30% (or such lower rate as may be specified
by an applicable treaty) on the corporate Non-U.S. Holder&rsquo;s effectively connected earnings and profits, subject to certain adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">See also the sections below titled &ldquo;&mdash;Backup Withholding
and Information Reporting&rdquo; and &ldquo;&mdash;Foreign Accounts&rdquo; for additional withholding rules that may apply to dividends
paid to certain foreign financial institutions or non-financial foreign entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Disposition of Common Stock or Pre-Funded Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Subject to the discussions below under the sections titled &ldquo;&mdash;Backup
Withholding and Information Reporting&rdquo; and &ldquo;&mdash;Foreign Accounts,&rdquo; a Non-U.S. Holder generally will not be subject
to U.S. federal income or withholding tax with respect to gain recognized on a sale or other disposition (other than a redemption treated
as a distribution, which will be taxable as described above under &ldquo;Distributions&rdquo;) of shares of Common Stock or Pre-Funded
Warrants unless:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">the gain is effectively connected with the Non-U.S. Holder&rsquo;s conduct of a trade or business in
the United States, and if an applicable income tax treaty so provides, the gain is attributable to a permanent establishment or fixed
base maintained by the Non-U.S. Holder in the United States; in these cases, the Non-U.S. Holder will be taxed on a net income basis at
the regular tax rates and in the manner applicable to U.S. persons, and if the Non-U.S. Holder is a corporation, an additional branch
profits tax at a rate of 30%, or a lower rate as may be specified by an applicable income tax treaty, may also apply;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">the Non-U.S. Holder is a nonresident alien present in the United States for 183 days or more in the
taxable year of the disposition and certain other requirements are met, in which case the Non-U.S. Holder will be subject to a 30% tax
(or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&rsquo;s country of
residence) on the net gain derived from the disposition, which may be offset by certain U.S.-source capital losses of the Non-U.S. Holder,
if any; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">the Common Stock constitutes a U.S. real property interest because we are, or have been at any time
during the five-year period preceding such disposition (or the Non-U.S. Holder&rsquo;s holding period of the Common Stock or Pre-Funded
Warrants, if shorter), a &ldquo;U.S. real property holding corporation,&rdquo; unless the Common Stock is regularly traded on an established
securities market, as defined by applicable Treasury Regulations, and the Non-U.S. Holder held no more than 5% of our outstanding Common
Stock, directly or indirectly, during the shorter of the five-year period ending on the date of the disposition or the period that the
Non-U.S. Holder held the Common Stock. Special rules may apply to the determination of the 5% threshold in the case of a holder of Pre-Funded
Warrants. Non-U.S. Holders are urged to consult their own tax advisors regarding the effect of holding Pre-Funded Warrants on the calculation
of such 5% threshold. Generally, a corporation is a &ldquo;U.S. real property holding corporation&rdquo; if the fair market value of its
&ldquo;U.S. real property interests&rdquo; (as defined in the Code and applicable regulations) equals or exceeds 50% of the sum of the
fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although
there can be no assurance, we believe that we are not currently, and we do not anticipate becoming, a &ldquo;U.S. real property holding
corporation&rdquo; for U.S. federal income tax purposes. No assurance can be provided that the Common Stock will be regularly traded on
an established securities market for purposes of the rules described above. Non-U.S. Holders are urged to consult their own tax advisors
regarding the U.S. federal income tax considerations that could result if we are, or become a &ldquo;U.S. real property holding corporation.&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">See the sections titled &ldquo;&mdash;Backup Withholding and Information
Reporting&rdquo; and &ldquo;&mdash;Foreign Accounts&rdquo; for additional information regarding withholding rules that may apply to proceeds
of a disposition of the Common Stock, Pre-Funded Warrants paid to foreign financial institutions or non-financial foreign entities.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Backup Withholding and Information Reporting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We must report annually to the IRS and to each Non-U.S. Holder the
gross amount of the distributions (including constructive distributions) on the Common Stock or, Pre-Funded Warrants paid to such holder
and the tax withheld, if any, with respect to such distributions. Non-U.S. Holders may have to comply with specific certification procedures
to establish that the holder is not a U.S. person (as defined in the Code) in order to avoid backup withholding at the applicable rate,
currently 24%, with respect to dividends (or constructive dividends) on the Common Stock or Pre-Funded Warrants. Generally, a holder will
comply with such procedures if it provides a properly executed IRS Form W-8BEN (or other applicable Form W-8) or otherwise meets documentary
evidence requirements for establishing that it is a Non-U.S. Holder, or otherwise establishes an exemption. Dividends paid to Non-U.S.
Holders subject to withholding of U.S. federal income tax, as described above under the heading &ldquo;Distributions,&rdquo; will generally
be exempt from U.S. backup withholding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Information reporting and backup withholding generally will apply
to the proceeds of a disposition of the Common Stock or Pre-Funded Warrants by a Non-U.S. Holder effected by or through the U.S. office
of any broker, U.S. or foreign, unless the holder certifies its status as a Non-U.S. Holder and satisfies certain other requirements,
or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition
proceeds to a Non-U.S. Holder where the transaction is effected outside the United States through a non-U.S. office of a broker. However,
for information reporting purposes, dispositions effected through a non-U.S. office of a broker with substantial U.S. ownership or operations
generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. Non-U.S. Holders should consult
their own tax advisors regarding the application of the information reporting and backup withholding rules to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Copies of information returns may be made available to the tax authorities
of the country in which the Non-U.S. Holder resides or is incorporated under the provisions of a specific treaty or agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Backup withholding is not an additional tax. Any amounts withheld
under the backup withholding rules from a payment to a Non-U.S. Holder can be refunded or credited against the Non-U.S. Holder&rsquo;s
U.S. federal income tax liability, if any, provided that an appropriate claim is timely filed with the IRS.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Foreign Accounts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The Foreign Account Tax Compliance Act, or FATCA, generally imposes
a 30% withholding tax on dividends (including constructive dividends) on the Common Stock and Pre-Funded Warrants if paid to a non-U.S.
entity unless (i) if the non-U.S. entity is a &ldquo;foreign financial institution,&rdquo; the non-U.S. entity undertakes certain due
diligence, reporting, withholding, and certification obligations, (ii) if the non-U.S. entity is not a &ldquo;foreign financial institution,&rdquo;
the non-U.S. entity identifies certain of its U.S. investors, if any, or (iii) the non-U.S. entity is otherwise exempt under FATCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Withholding under FATCA generally will apply to payments of dividends
(including constructive dividends) on our Common Stock and Pre-Funded Warrants. While withholding under FATCA would have also applied
to payments of gross proceeds from a sale or other disposition of the Common Stock or Pre-Funded Warrants, under proposed U.S. Treasury
Regulations withholding on payments of gross proceeds is currently not required. Although such regulations are not final, applicable withholding
agents may rely on the proposed regulations until final regulations are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">An intergovernmental agreement between the United States and an
applicable foreign country may modify the requirements described in this section. Under certain circumstances, a holder may be eligible
for refunds or credits of the tax. Holders should consult their own tax advisors regarding the possible implications of FATCA on their
investment in the Common Stock or Pre-Funded Warrants.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  "></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif">Federal Estate Tax</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Common stock owned or treated as owned by an individual who is not
a citizen or resident of the United States (as specially defined for U.S. federal estate tax purposes) at the time of death will be included
in the individual&rsquo;s gross estate for U.S. federal estate tax purposes and, therefore, may be subject to U.S. federal estate tax,
unless an applicable estate tax or other treaty provides otherwise. The foregoing may also apply to Pre-Funded Warrants. A Non-U.S. Holder
should consult his, her, or its own tax advisor regarding the U.S. federal estate tax consequences of the ownership or disposition of
shares of the Common Stock and Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The preceding discussion of material U.S. federal tax considerations
is for information only. It is not tax advice. Prospective investors should consult their own tax advisors regarding the particular U.S.
federal, state, local and non-U.S. tax consequences of purchasing, holding and disposing of the Common Stock or Pre-Funded Warrants, including
the consequences of any proposed changes in applicable laws.&nbsp;</P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif;   text-transform: uppercase; letter-spacing: 0.6pt; text-align: center"><A NAME="a_012"></A>SECURITY
OWNERSHIP OF<BR>
CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The following table sets forth information with respect to the beneficial
ownership of our Common Stock, as of December&nbsp;20, 2024:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">each person or group of affiliated persons known by us to beneficially own more than 5% of our Common
Stock;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">each of our executive officers;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">each of our directors; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">all of our current executive officers and directors as a group.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The following table sets forth information, as of December&nbsp;20,
2024, or as otherwise set forth below, with respect to the beneficial ownership of our Common Stock (i)&nbsp;all persons known to us to
be the beneficial owners of more than 5% of the outstanding shares of our Common Stock, (ii)&nbsp;each of our directors and our executive
officer named in the Summary Compensation Table, and (iii)&nbsp;all of our directors and our current executive officer as a group. As
of December&nbsp;20, 2024, we had 4,868,268&nbsp;shares of Common Stock outstanding. We have based our calculation of the percentage of
beneficial ownership of our Common Stock after this Offering on 34,280,032&nbsp;shares of our Common Stock outstanding, which gives effect
to the issuance of 29,411,764 shares of our Common Stock issued in this Offering based on an assumed public offering price of $0.34 per
share (which is the last reported sale price of our Common Stock on NYSE American on December&nbsp;20, 2024) and assuming no exercise
of the representative&rsquo;s over-allotment option and no sale of Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Unless otherwise indicated the mailing address of each of the stockholders
below is c/o Scorpius Holdings, Inc., 627 Davis Drive, Suite 300, Morrisville, North Carolina 27560. Except as otherwise indicated, and
subject to applicable community property laws, except to the extent authority is shared by both spouses under applicable law, the Company
believes the persons named in the table have sole voting and investment power with respect to all shares of Common Stock held by them.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Name of Beneficial
    Owner</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Common
    Stock</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Shares
    subject to Options, Warrants</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Total
    Number of Shares Beneficially Owned</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Percentage
    Ownership Prior to this Offering</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Percentage Ownership
    After this Offering</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left">Named Executive Officers &amp; Directors</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 37%; text-align: left">Jeffrey Wolf (Chairman of the Board of Directors, Chief Executive Officer and President) (2)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">17,970</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">29,067</TD><TD STYLE="width: 1%; text-align: left">(1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">47,037</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">William L. Ostrander (Chief Financial Officer and Secretary)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,525</TD><TD STYLE="text-align: left">(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,557</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">John K. A. Prendergast, Ph.D. (Director)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,191</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,695</TD><TD STYLE="text-align: left">(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,886</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">John Monahan, Ph.D. (Director)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,224</TD><TD STYLE="text-align: left">(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,224</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Edward B. Smith, III (Director)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,224</TD><TD STYLE="text-align: left">(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,224</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 12pt">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic">5% Stockholders</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Ramnarain Joseph Jaigobind (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">309,034</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">309,034</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.35</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">[&bull;]%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">3i, LP (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">257,709</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">254,006</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">511,715</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.99</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">[&bull;]%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 12pt">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">All Current Executive Officers and Directors, as a group (5 persons)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,193</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,735</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,928</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.12</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">_______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">* less than 1%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD><FONT STYLE="font-size: 10pt">Represents shares subject to options that are currently vested and options that will vest and become
exercisable within 60 days of December&nbsp;20, 2024.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD><FONT STYLE="font-size: 10pt">Includes warrants to purchase up to 12,500 shares of Common Stock acquired in our May 2024 public offering.
Includes 55 shares of Common Stock held by Orion Holdings V, LLC and 51 shares of Common Stock held by Seed-One Holdings VI, LLC, entities
for which Mr. Wolf serves as the managing member. Mr. Wolf is deemed to beneficially own the shares held by such entities as in his role
as the managing member he has the control over the voting and disposition of any shares held by these entities. Does not include 132 shares
of Common Stock beneficially owned by Mr. Wolf&rsquo;s children&rsquo;s trust of which Mr. Wolf is not the trustee. Mr. Wolf disclaims
beneficial ownership of these shares except to the extent of any pecuniary interest (as defined in Rule 16a-1(a)(2) promulgated under
the Exchange Act) that he may have in such entities. In addition, if our company is traded on a recognized national exchange while Mr.
Wolf is employed by us and the market capitalization of our company is equal to or in excess of $500 million for at least fifteen consecutive
trading days, then Mr. Wolf will be entitled to receive an additional stock option equal to 2% of the then outstanding shares of our Common
Stock, at an exercise price equal to the then current market price as determined in good faith by the board. Does not include 103,908
shares of Common Stock to be issued upon conversion of the Restated Note issued to Elusys Holdings, the conversion of which is subject
to NYSE American approval, if required, and if approved, would result in Mr. Wolf beneficially owning 5.0% of our Common Stock after this
Offering.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD><FONT STYLE="font-size: 10pt">Based on a Schedule&nbsp;13G filed by Ramarain Joseph Jaigobind (&ldquo;Mr. Jaigobind&rdquo;). Mr. Jaigobind
is a principal of ThinkEquity and has sole voting and dispositive power over shares beneficially owned by himself and ThinkEquity. Mr.
Jaigobind&rsquo;s address is c/o ThinkEquity LLC, 17 State Street, 41st Floor, New York, NY 10004. Does not include any warrants to be
issued to the representative or its designees in this Offering.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD><FONT STYLE="font-size: 10pt">Based on a Schedule 13G filed by 3i, LP, a Delaware limited partnership (&ldquo;3i&rdquo;); 3i Management
LLC, a Delaware limited liability company (&ldquo;3i Management&rdquo;); and Maier Joshua Tarlow (&ldquo;Mr. Tarlow&rdquo;) (collectively,
the &ldquo;3i Parties&rdquo;), and on information available to us, the 3i Parties hold (i) 257,709 shares of Common Stock, (ii) pre-funded
warrants exercisable for up to 1,500,000 shares of Common Stock, subject to a 9.99% beneficial ownership limitation provision, (iii) Common
Stock purchase warrants exercisable for up to 12,566,667 shares of Common Stock, subject to a 4.99% beneficial ownership limitation provision
and (iv) Secured Convertible Notes convertible into a maximum of 31,538,334 shares of Common Stock (including shares issuable in respect
of interest and the Make-Whole Amount, as such term is defined in the Secured Convertible Notes), subject to a 4.99% beneficial ownership
limitation provision</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in">3i Management is the general partner of 3i, and Mr. Tarlow
is the manager of 3i Management. As such, Mr. Tarlow exercises sole voting and investment discretion over securities beneficially owned
directly or indirectly by 3i and 3i Management. Mr. Tarlow disclaims beneficial ownership of the securities beneficially owned directly
by 3i and indirectly by 3i Management. The business address of each of the aforementioned parties is 2 Wooster Street, 2nd Floor, New
York, NY 10013. We have been advised that none of Mr. Tarlow, 3i Management or 3i is a member of the Financial Industry Regulatory Authority
(&ldquo;FINRA&rdquo;) or an independent broker-dealer, or an affiliate or associated person of a FINRA member or independent broker-dealer.
The securities beneficially owned by 3i in the table above are calculated as of December 20, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The following table sets forth information, as of December&nbsp;20,
2024, or as otherwise set forth below, with respect to the beneficial ownership of the Common Stock of each of our subsidiaries set forth
below of (i)&nbsp;each of our directors and our executive officer named in the Summary Compensation Table, and (ii)&nbsp;all of our directors
and our executive officer as a group.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD COLSPAN="17" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt; line-height: 107%"><B>Common
                                            Stock Beneficially Owned (%)</B></FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">Name of Beneficial
    Owner</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt; line-height: 107%"><B>Pelican
                                            Therapeutics, Inc.(1)</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt; line-height: 107%"><B>Skunkworx
                                            Bio, Inc.(2)</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt; line-height: 107%"><B>Abacus
                                            Biotech, Inc.(2)</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt; line-height: 107%"><B>Scorpius
                                            Biomanufacturing, Inc. (2)</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt; line-height: 107%"><B>Blackhawk
                                            Bio, Inc.(2)</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; font-size: 10pt; text-align: left">Jeffrey Wolf</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">3.1</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5.0</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5.0</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5.0</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5.0</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">William Ostrander</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.0</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">John K. A. Prendergast, Ph.D.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">John Monahan, Ph.D.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Edward B. Smith, III</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt; line-height: 107%">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify">Total</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.4</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.0</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.0</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6.0</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.0</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0">* less than 1%</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD><FONT STYLE="font-size: 10pt">The shares of common stock of Pelican were issued to each individual prior to Pelican becoming a subsidiary
of our company.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD><FONT STYLE="font-size: 10pt">Consists of options issued in each applicable subsidiary pursuant to our 2021 Subsidiaries Stock Incentive
Plan. Percent is the beneficial ownership percent for each individual in the applicable subsidiary.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif;   text-transform: uppercase; letter-spacing: 0.6pt; text-align: center"><A NAME="a_013"></A>Underwriting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">ThinkEquity LLC is acting as the representative of the several underwriters
in this Offering. On &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
we entered into an underwriting agreement with the Representative (the &ldquo;Underwriting Agreement&rdquo;). Subject to the terms and
conditions of the Underwriting Agreement, we have agreed to sell to each underwriter named below, and each underwriter named below has
severally agreed to purchase the number of Shares and the number of Pre-Funded Warrants listed next to each underwriter&rsquo;s name in
the following table, at the public offering price less the underwriting discounts and commissions, as set forth on the cover page of this
prospectus and as indicated below:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 8pt"><B>Underwriter</B></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Number of Shares</B></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Number of Pre-Funded Warrants</B></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 40%; text-indent: 16.2pt"><FONT STYLE="font-size: 10pt">ThinkEquity LLC</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 27%; border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 25%; border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Total:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0">The underwriters have committed to purchase all of the Shares and
Pre-Funded Warrants offered by us in this Offering, other than those securities covered by the over-allotment option described below.
The obligations of the underwriters may be terminated upon the occurrence of certain events specified in the Underwriting Agreement. Furthermore,
pursuant to the Underwriting Agreement, the underwriters&rsquo; obligations are subject to customary conditions, representations and warranties,
such as receipt by the underwriters of officers&rsquo; certificates and legal opinions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The underwriters are offering the Shares and Pre-Funded Warrants
subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel and other
conditions. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in
part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The underwriters propose to offer the Shares to the public at the
public offering price set forth on the cover of the prospectus. After the Shares are released for sale to the public, the underwriters
may from time to time change the offering price and other selling terms.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Over-Allotment Option</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We have granted to the Representative an option, exercisable for
45 days from the date of this prospectus, to purchase up to 4,411,764&nbsp;additional Shares and/or 4,411,764&nbsp;Pre-Funded Warrants
to purchase 4,411,764&nbsp;shares of common stock (15% of the Shares and Pre-Funded Warrants sold in this Offering) at the initial public
offering price (minus $0.0002 per Pre-Funded Warrant) less the underwriting discounts and commissions. The underwriters may exercise the
option solely for the purpose of covering over-allotments, if any, in connection with this Offering. To the extent that the option is
exercised, each underwriter must purchase additional Shares and/or Pre-Funded Warrants in an amount that is approximately proportionate
to that underwriter&rsquo;s initial purchase commitment (set forth in the table above). Any Shares and/or Pre-Funded Warrants issued or
sold under the option will be issued and sold on the same terms and conditions as the other Shares and/or Pre-Funded Warrants that are
the subject of this Offering.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Discounts, Commissions and Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The Representative has advised us that the underwriters propose
to offer the Shares and Pre-Funded Warrants directly to the public at the public offering price per share set forth on the cover page
of this prospectus and as set forth below. After the offering to the public, the offering price and other selling terms may be changed
by the underwriters without changing the proceeds we will receive from the underwriters. Any Shares and Pre-Funded Warrants sold by the
underwriters to securities dealers will be sold at the public offering price less a concession not in excess of $[&bull;] per Share or
per Pre-Funded Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The following table shows the public offering price, underwriting
discounts and commissions and proceeds, before expenses, to us.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Per Share</B></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>Per
    Pre-Funded Warrant</B></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>Total
    Without Over-Allotment</B></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>Total
    With Full Over-Allotment</B></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 35%"><FONT STYLE="font-size: 10pt">Public offering price</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 13%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Underwriting discount (7.0%)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Proceeds to us, before expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0">In addition, we have agreed to reimburse the Representative for certain
of its fees and expenses, provided that such fees shall not collectively exceed $145,000 in the aggregate. We have also agreed to pay
a non-accountable expense allowance to the Representative equal to 1.0% of the gross proceeds received in this Offering, which is not
included in the underwriting discounts and commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We estimate that the total expenses in connection with this Offering
payable by us, excluding the total underwriting discounts and commissions and non-accountable expense allowance, will be approximately
$400,000.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Representative&rsquo;s Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">If the gross proceeds from this Offering are at least $11 million,
we have agreed to issue to the Representative, or its designees, warrants to purchase up to a total of 5% of the number of shares of Common
Stock and Pre-Funded Warrants sold in this Offering. The Representative&rsquo;s Warrants will be exercisable at any time, and from time
to time, in whole or in part, during the four and one-half year period commencing 180 days from commencement of sales of securities in
the Offering at a per share price equal to 125% of the public offering price per share of Common Stock in the Offering. The Representative&rsquo;s
Warrants will provide for customary anti-dilution provisions (the exercise price and number of shares of Common Stock issuable upon exercise
is subject to appropriate adjustment in the event of share dividends, share splits, reorganizations or similar events affecting our shares
of Common Stock and the exercise price) consistent with FINRA Rule 5110, and further, the number of shares underlying the Representative&rsquo;s
Warrants shall be reduced if necessary to comply with FINRA rules or regulations.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Right of First Refusal</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">In addition, for a period of nine (9) months from the date of the
closing of this Offering, we agreed to grant to the Representative an irrevocable right of first refusal to act as sole investment banker,
sole book-runner and/or sole placement agent, at the Representative&rsquo;s sole discretion, for each and every future public and private
equity and debt offering, including all equity linked financings, during such nine (9) month period for us, or any successor to or any
subsidiary of us, on terms agreed to by both us and the Representative. The Representative will have the sole right to determine whether
or not any other broker-dealer shall have the right to participate in any such offering and the economic terms of any such participation.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Indemnification</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We have agreed to indemnify the underwriters against specified liabilities,
including liabilities under the Securities Act, and to contribute to payments the underwriters may be required to make in respect thereof.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Discretionary Accounts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The underwriters do not intend to confirm sales of the securities
offered hereby to any accounts over which they have discretionary authority.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  "></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif">Lock-Up Agreements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Pursuant to &ldquo;lock-up&rdquo; agreements, we have agreed for
a period of ninety (90) days after the date of this prospectus and our executive officers and directors have agreed for a period of ninety
(90) days after the date of this prospectus, subject to customary exceptions, without the prior written consent of the Representative,
not to, directly or indirectly, offer pledge, sell, contract to sell, grant, lend or otherwise transfer or dispose of any of shares of
(or enter into any transaction or device that is designed to, or could be expected to, result in the transfer or disposition by any person
at any time in the future of) our common stock, enter into any swap or other derivatives transaction that transfers to another, in whole
or in part, any of the economic benefits or risks of ownership of shares of our common stock, make any demand for or exercise any right
or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any shares of common
stock or securities convertible into or exercisable or exchangeable for common stock or any other securities of ours or publicly disclose
the intention to do any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Additionally, we agreed that for a period of nine (9)&nbsp;months
after the closing of this Offering we will not directly or indirectly in any &ldquo;at-the-market,&rdquo; continuous equity, equity lines,
or variable rate transaction, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of shares of our common
stock or any securities convertible into or exercisable or exchangeable for our shares of common stock, without the prior written consent
of ThinkEquity.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Electronic Offer, Sale and Distribution of Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">This prospectus in electronic format may be made available on websites
or through other online services maintained by the underwriter, or by its affiliates. Other than this prospectus in electronic format,
the information on the underwriters&rsquo; website and any information contained in any other website maintained by an underwriter is
not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed
by us or the underwriters in their capacity as underwriters, and should not be relied upon by investors.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Stabilization</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">In connection with this Offering, the underwriters may engage in
stabilizing transactions, over-allotment transactions, syndicate-covering transactions, penalty bids and purchases to cover positions
created by short sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Stabilizing transactions permit bids to purchase securities so long
as the stabilizing bids do not exceed a specified maximum and are engaged in for the purpose of preventing or retarding a decline in the
market price of the securities while this Offering is in progress.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Over-allotment transactions involve sales by the underwriters of
securities in excess of the number of securities that underwriters are obligated to purchase. This creates a syndicate short position
which may be either a covered short position or a naked short position. In a covered short position, the number of securities over-allotted
by the underwriters is not greater than the number of securities that they may purchase in the over-allotment option. In a naked short
position, the number of securities involved is greater than the number of securities in the over-allotment option. The underwriters may
close out any short position by exercising their over-allotment option and/or purchasing securities in the open market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Syndicate covering transactions involve purchases of securities
in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of
securities to close out the short position, the underwriters will consider, among other things, the price of securities available for
purchase in the open market as compared with the price at which they may purchase securities through exercise of the over-allotment option.
If the underwriters sell more securities than could be covered by exercise of the over-allotment option and, therefore, have a naked short
position, the position can be closed out only by buying securities in the open market. A naked short position is more likely to be created
if the underwriters are concerned that after pricing there could be downward pressure on the price of the securities in the open market
that could adversely affect investors who purchase in this Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Penalty bids permit the Representative to reclaim a selling concession
from a syndicate member when the securities originally sold by that syndicate member are purchased in stabilizing or syndicate covering
transactions to cover syndicate short positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">These stabilizing transactions, syndicate covering transactions
and penalty bids may have the effect of raising or maintaining the market price of our securities or preventing or retarding a decline
in the market price of our securities. As a result, the price of our securities in the open market may be higher than it would otherwise
be in the absence of these transactions. Neither we nor the underwriters make any representation or prediction as to the effect that the
transactions described above may have on the price of our securities. These transactions may be effected on NYSE American, in the over-the-counter
market or otherwise and, if commenced, may be discontinued at any time.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Passive Market Making</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">In connection with this Offering, underwriters and selling group
members may engage in passive market making transactions in our common stock on the national securities market on which our common stock
is trading in accordance with Rule 103 of Regulation M under the Exchange Act , during a period before the commencement of offers or sales
of the shares and extending through the completion of the distribution. A passive market maker must display its bid at a price not in
excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&rsquo;s
bid, then that bid must then be lowered when specified purchase limits are exceeded.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Determination of Offering Price</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The public offering price of the securities that we are offering
will be negotiated between us and the Representative based on, among other things, the trading price of our Common Stock prior to this
Offering. Other factors considered in determining the public offering price of the securities include our history and prospects, the stage
of development of our business, our business plans for the future and the extent to which they have been implemented, an assessment of
our management, general conditions of the securities markets at the time of the offering and such other factors as were deemed relevant.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Other Relationships</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">From time to time, certain of the underwriters and/or their respective
affiliates may have provided, and may in the future provide, various investment banking and other financial services for us for which
they may receive customary fees. In the course of its business, certain of the underwriters and their respective affiliates may actively
trade our securities or loans for its own account or for the accounts of customers, and, accordingly, the underwriters and their respective
affiliates may at any time hold long or short positions in such securities or loans.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">December Private Placement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">On December&nbsp;6, 2024, we consummated the December Note Offering
and December Warrants, resulting in aggregate net proceeds to us of approximately $3.3&nbsp;million, before deducting underwriting discounts
and other offering expenses. ThinkEquity served as our financial advisor and received a financial advisory fee of $285,000, equal to 8%
of the net proceeds received by us at the closing of the December Note Offering.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">November&nbsp;2024 Note</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">On November 27, 2024, we issued the November 2024 Note. ThinkEquity
served as our financial advisor in connection with the placement of the November 2024 Note and did not receive a fee in connection with
such service.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  "></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif">August 2024 Public Offering</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">On August 19, 2024, we consummated the August Offering of 2,428,000
shares of Common Stock and 11,947,000&nbsp;pre-funded warrants to purchase up to 11,947,000 shares of Common Stock (including pre-funded
warrants issued upon the exercise of the underwriters&rsquo; over-allotment option) for a purchase price of $1.00 per share of Common
Stock or pre-funded warrant (inclusive of the pre-funded warrant exercise price), resulting in aggregate gross proceeds of approximately
$14.4 million, before deducting underwriting discounts and other offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">ThinkEquity served as representative of the several underwriters
named in the Underwriting Agreement that we entered into on August 16, 2024 and we paid ThinkEquity a cash discount equal to 7% of the
gross offering proceeds, a 1% non-accountable expense allowance and reimbursed certain expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">In addition, for a period of eight (8) months from the date of the
closing of the August Offering, we agreed to grant to ThinkEquity, an irrevocable right of first refusal to act as sole investment banker,
sole book-runner and/or sole placement agent, at the Representative&rsquo;s sole discretion, for each and every future public and private
equity and debt offering, including all equity linked financings, during such eight (8) month period for us, or any successor to or any
subsidiary of us, on terms agreed to by both us and the Representative.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">May 2024 Public Offering</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">On May 16, 2024, we closed a public offering of 149,100 Units and
150,900 Pre-Funded Units for a purchase price of $20.00 per Unit and per Pre-Funded Unit (inclusive of the pre-funded warrant exercise
price), resulting in aggregate gross proceeds of approximately $6.0&nbsp;million, before deducting underwriting discounts and other offering
expenses and we paid ThinkEquity a cash discount equal to 7% of the gross offering proceeds, a 1% non-accountable expense allowance and
reimbursed certain expenses and reimbursed certain expenses. ThinkEquity also partially exercised its over-allotment option and purchased
6,545&nbsp;Common Warrants and 6,545 shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">In addition, for a period of eight (8) months from the date of the
closing of that offering, we agreed to grant to ThinkEquity, an irrevocable right of first refusal to act as sole investment banker, sole
book-runner and/or sole placement agent, at ThinkEquity&rsquo;s sole discretion, for each and every future public and private equity and
debt offering, including all equity linked financings, during such eight (8) month period for us, or any successor to or any subsidiary
of us, on terms agreed to by both us and ThinkEquity.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">March 2024 Public Offering</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">On March 12, 2024, we closed the offering contemplated by the underwriting
agreement that we entered into on March 7, 2024 with ThinkEquity, as representative of the several underwriters named therein, pursuant
to which we issued and sold 50,000&nbsp;shares of our Common Stock at a price of $30.00 per share for gross proceeds of $1,500,000, and
we paid ThinkEquity a cash discount equal to 7% of the gross offering proceeds and reimbursed certain expenses. In addition, for a period
of six (6) months from the date of the closing of that offering, we agreed to grant to ThinkEquity, an irrevocable right of first refusal
to act as sole investment banker, sole book-runner and/or sole placement agent, at ThinkEquity&rsquo;s sole discretion, for each and every
future public and private equity and debt offering, including all equity linked financings, during such six (6) month period for us, or
any successor to or any subsidiary of us, on terms agreed to by both us and ThinkEquity.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Offer Restrictions Outside of the United States</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Other than in the United States, no action has been taken by us
or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action
for that purpose is required. The Securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this
prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed
or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations
of that country or jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe
any restrictions relating to this Offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell
or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation
is unlawful.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  "></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif">Australia</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">This prospectus is not a disclosure document under Chapter 6D of
the Australian Corporations Act, has not been lodged with the Australian Securities and Investments Commission and does not purport to
include the information required of a disclosure document under Chapter 6D of the Australian Corporations Act. Accordingly, (i) the offer
of the securities under this prospectus is only made to persons to whom it is lawful to offer the securities without disclosure under
Chapter 6D of the Australian Corporations Act under one or more exemptions set out in section 708 of the Australian Corporations Act,
(ii) this prospectus is made available in Australia only to those persons as set forth in clause (i) above, and (iii) the offeree must
be sent a notice stating in substance that by accepting this offer, the offeree represents that the offeree is such a person as set forth
in clause (i) above, and, unless permitted under the Australian Corporations Act, agrees not to sell or offer for sale within Australia
any of the securities sold to the offeree within 12 months after its transfer to the offeree under this prospectus.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Canada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The securities may be sold only to purchasers purchasing, or deemed
to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection
73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements,
Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption from, or in a
transaction not subject to, the prospectus requirements of applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Securities legislation in certain provinces or territories of Canada
may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation,
provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities
legislation of the purchaser&rsquo;s province or territory. The purchaser should refer to any applicable provisions of the securities
legislation of the purchaser&rsquo;s province or territory for particulars of these rights or consult with a legal advisor.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The information in this document does not constitute a public offer
of the securities, whether by way of sale or subscription, in the People&rsquo;s Republic of China (excluding, for purposes of this paragraph,
Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan). The securities may not be offered or sold directly
or indirectly in the PRC to legal or natural persons other than directly to &ldquo;qualified domestic institutional investors.&rdquo;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">European Economic Area&mdash;Belgium, Germany,
Luxembourg and Netherlands</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The information in this document has been prepared on the basis
that all offers of securities will be made pursuant to an exemption under the Directive 2003/71/EC (&ldquo;Prospectus Directive&rdquo;),
as implemented in Member States of the European Economic Area (each, a &ldquo;Relevant Member State&rdquo;), from the requirement to produce
a prospectus for offers of securities. An offer to the public of securities has not been made, and may not be made, in a Relevant Member
State except pursuant to one of the following exemptions under the Prospectus Directive as implemented in that Relevant Member State:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">to legal entities that are authorized or regulated to operate in the financial markets or, if not so
authorized or regulated, whose corporate purpose is solely to invest in securities;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">to any legal entity that has two or more of (i) an average of at least 250 employees during its last
fiscal year; (ii) a total balance sheet of more than &euro;43,000,000 (as shown on its last annual unconsolidated or consolidated financial
statements) and (iii) an annual net turnover of more than &euro;50,000,000 (as shown on its last annual unconsolidated or consolidated
financial statements);</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">to fewer than 100 natural or legal persons (other than qualified investors within the meaning of Article
2(1)(e) of the Prospectus Directive) subject to obtaining the prior consent of the Company or any underwriter for any such offer; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no
such offer of securities shall result in a requirement for the publication by the Company of a prospectus pursuant to Article 3 of the
Prospectus Directive.</FONT></TD></TR></TABLE>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">France</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">This document is not being distributed in the context of a public
offering of financial securities (offre au public de titres financiers) in France within the meaning of Article L.411-1 of the French
Monetary and Financial Code (Code Mon&eacute;taire et Financier) and Articles 211-1 et seq. of the General Regulation of the French Autorit&eacute;
de march&eacute;s financiers (&ldquo;AMF&rdquo;). The securities have not been offered or sold and will not be offered or sold, directly
or indirectly, to the public in France.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">This document and any other offering material relating to the securities
have not been, and will not be, submitted to the AMF for approval in France and, accordingly, may not be distributed or caused to distributed,
directly or indirectly, to the public in France.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Such offers, sales and distributions have been and shall only be
made in France to (i) qualified investors (investisseurs qualifi&eacute;s) acting for their own account, as defined in and in accordance
with Articles L.411-2-II-2&deg; and D.411-1 to D.411-3, D.744-1, D.754-1 ;and D.764-1 of the French Monetary and Financial Code and any
implementing regulation and/or (ii) a restricted number of non-qualified investors (cercle restreint d&rsquo;investisseurs) acting for
their own account, as defined in and in accordance with Articles L.411-2-II-2&deg; and D.411-4, D.744-1, D.754-1; and D.764-1 of the French
Monetary and Financial Code and any implementing regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Pursuant to Article 211-3 of the General Regulation of the AMF,
investors in France are informed that the securities cannot be distributed (directly or indirectly) to the public by the investors otherwise
than in accordance with Articles L.411-1, L.411-2, L.412-1 and L.621-8 to L.621-8-3 of the French Monetary and Financial Code.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Hong Kong</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Neither the information in this document nor any other document
relating to the offer has been delivered for registration to the Registrar of Companies in Hong Kong, and its contents have not been reviewed
or approved by any regulatory authority in Hong Kong, nor have we been authorized by the Securities and Futures Commission in Hong Kong.
This document does not constitute an offer or invitation to the public in Hong Kong to acquire securities. Accordingly, unless permitted
by the securities laws of Hong Kong, no person may issue or have in its possession for the purpose of issue, this document or any advertisement,
invitation or document relating to the securities, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are
likely to be accessed or read by, the public in Hong Kong other than in relation to securities which are intended to be disposed of only
to persons outside Hong Kong or only to &ldquo;professional investors&rdquo; (as such term is defined in the Securities and Futures Ordinance
(Cap. 571 of the Laws of Hong Kong) (&ldquo;SFO&rdquo;) and the subsidiary legislation made thereunder) or in circumstances which do not
result in this document being a &ldquo;prospectus&rdquo; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance
of Hong Kong (Cap. 32 of the Laws of Hong Kong) (the &ldquo;CO&rdquo;) or which do not constitute an offer or an invitation to the public
for the purposes of the SFO or the CO. The offer of the securities is personal to the person to whom this document has been delivered
by or on behalf of our company, and a subscription for securities will only be accepted from such person. No person to whom a copy of
this document is issued may issue, circulate or distribute this document in Hong Kong or make or give a copy of this document to any other
person. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of this document,
you should obtain independent professional advice. No document may be distributed, published or reproduced (in whole or in part), disclosed
by or to any other person in Hong Kong or to any person to whom the offer of sale of the securities would be a breach of the CO or SFO.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  "></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif">Ireland</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The information in this document does not constitute a prospectus
under any Irish laws or regulations and this document has not been filed with or approved by any Irish regulatory authority as the information
has not been prepared in the context of a public offering of securities in Ireland within the meaning of the Irish Prospectus (Directive
2003/71/EC) Regulations 2005 (the &ldquo;Prospectus Regulations&rdquo;). The securities have not been offered or sold, and will not be
offered, sold or delivered directly or indirectly in Ireland by way of a public offering, except to (i) qualified investors as defined
in Regulation 2(l) of the Prospectus Regulations and (ii) fewer than 100 natural or legal persons who are not qualified investors.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The securities offered by this prospectus have not been approved
or disapproved by the Israeli Securities Authority (the ISA), nor have such securities been registered for sale in Israel. The shares
may not be offered or sold, directly or indirectly, to the public in Israel, absent the publication of a prospectus. The ISA has not issued
permits, approvals or licenses in connection with this Offering or publishing the prospectus; nor has it authenticated the details included
herein, confirmed their reliability or completeness, or rendered an opinion as to the quality of the securities being offered. Any resale
in Israel, directly or indirectly, to the public of the securities offered by this prospectus is subject to restrictions on transferability
and must be effected only in compliance with the Israeli securities laws and regulations.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Italy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The offering of the securities in the Republic of Italy has not
been authorized by the Italian Securities and Exchange Commission (Commissione Nazionale per le Societ&agrave; e la Borsa (&ldquo;CONSOB&rdquo;)
pursuant to the Italian securities legislation and, accordingly, no offering material relating to the securities may be distributed in
Italy and such securities may not be offered or sold in Italy in a public offer within the meaning of Article 1.1(t) of Legislative Decree
No. 58 of 24 February 1998 (&ldquo;Decree No. 58&rdquo;), other than:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">to Italian qualified investors, as defined in Article 100 of Decree no.58 by reference to Article 34-ter
of CONSOB Regulation no. 11971 of 14 May 1999 (&ldquo;Regulation no. 1197l&rdquo;) as amended (&ldquo;Qualified Investors&rdquo;); and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">in other circumstances that are exempt from the rules on public offer pursuant to Article 100 of Decree
No. 58 and Article 34-ter of Regulation No. 11971 as amended.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Any offer, sale or delivery of the securities or distribution of any offer document relating to the
securities in Italy (excluding placements where a Qualified Investor solicits an offer from the issuer) under the paragraphs above must
be:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">made by investment firms, banks or financial intermediaries permitted to conduct such activities in
Italy in accordance with Legislative Decree No. 385 of 1 September 1993 (as amended), Decree No. 58, CONSOB Regulation No. 16190 of 29
October 2007 and any other applicable laws; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">in compliance with all relevant Italian securities, tax and exchange controls and any other applicable
laws.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Any subsequent distribution of the securities in Italy must be made
in compliance with the public offer and prospectus requirement rules provided under Decree No. 58 and the Regulation No. 11971 as amended,
unless an exception from those rules applies. Failure to comply with such rules may result in the sale of such securities being declared
null and void and in the liability of the entity transferring the securities for any damages suffered by the investors.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  "></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif">Japan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The securities have not been and will not be registered under Article
4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948), as amended (the &ldquo;FIEL&rdquo;) pursuant
to an exemption from the registration requirements applicable to a private placement of securities to Qualified Institutional Investors
(as defined in and in accordance with Article 2, paragraph 3 of the FIEL and the regulations promulgated thereunder). Accordingly, the
securities may not be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan other than
Qualified Institutional Investors. Any Qualified Institutional Investor who acquires securities may not resell them to any person in Japan
that is not a Qualified Institutional Investor, and acquisition by any such person of securities is conditional upon the execution of
an agreement to that effect.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Portugal</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">This document is not being distributed in the context of a public
offer of financial securities (oferta p&uacute;blica de valores mobili&aacute;rios) in Portugal, within the meaning of Article 109 of
the Portuguese Securities Code (C&oacute;digo dos Valores Mobili&aacute;rios). The securities have not been offered or sold and will not
be offered or sold, directly or indirectly, to the public in Portugal. This document and any other offering material relating to the securities
have not been, and will not be, submitted to the Portuguese Securities Market Commission (Comiss&abreve;o do Mercado de Valores Mobili&aacute;rios)
for approval in Portugal and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in Portugal,
other than under circumstances that are deemed not to qualify as a public offer under the Portuguese Securities Code. Such offers, sales
and distributions of securities in Portugal are limited to persons who are &ldquo;qualified investors&rdquo; (as defined in the Portuguese
Securities Code). Only such investors may receive this document and they may not distribute it or the information contained in it to any
other person.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Sweden</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">This document has not been, and will not be, registered with or
approved by Finansinspektionen (the Swedish Financial Supervisory Authority). Accordingly, this document may not be made available, nor
may the securities be offered for sale in Sweden, other than under circumstances that are deemed not to require a prospectus under the
Swedish Financial Instruments Trading Act (1991:980) (Sw. lag (1991:980) om handel med finansiella instrument). Any offering of securities
in Sweden is limited to persons who are &ldquo;qualified investors&rdquo; (as defined in the Financial Instruments Trading Act). Only
such investors may receive this document and they may not distribute it or the information contained in it to any other person.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">Switzerland</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The securities may not be publicly offered in Switzerland and will
not be listed on the SIX Swiss Exchange (&ldquo;SIX&rdquo;) or on any other stock exchange or regulated trading facility in Switzerland.
This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the
Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing
rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering material
relating to the securities may be publicly distributed or otherwise made publicly available in Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Neither this document nor any other offering material relating to
the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be
filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority (FINMA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">This document is personal to the recipient only and not for general
circulation in Switzerland.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  "></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif">United Arab Emirates</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Neither this document nor the securities have been approved, disapproved
or passed on in any way by the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates,
nor has the Company received authorization or licensing from the Central Bank of the United Arab Emirates or any other governmental authority
in the United Arab Emirates to market or sell the securities within the United Arab Emirates. This document does not constitute and may
not be used for the purpose of an offer or invitation. No services relating to the securities, including the receipt of applications and/or
the allotment or redemption of such shares, may be rendered within the United Arab Emirates by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">No offer or invitation to subscribe for securities is valid or permitted
in the Dubai International Financial Centre.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif;  ">United Kingdom</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Neither the information in this document nor any other document
relating to the offer has been delivered for approval to the Financial Services Authority in the United Kingdom and no prospectus (within
the meaning of section 85 of the Financial Services and Markets Act 2000, as amended (&ldquo;FSMA&rdquo;) has been published or is intended
to be published in respect of the securities. This document is issued on a confidential basis to &ldquo;qualified investors&rdquo; (within
the meaning of section 86(7) of FSMA) in the United Kingdom, and the securities may not be offered or sold in the United Kingdom by means
of this document, any accompanying letter or any other document, except in circumstances which do not require the publication of a prospectus
pursuant to section 86(1) FSMA. This document should not be distributed, published or reproduced, in whole or in part, nor may its contents
be disclosed by recipients to any other person in the United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Any invitation or inducement to engage in investment activity (within
the meaning of section 21 of FSMA) received in connection with the issue or sale of the securities has only been communicated or caused
to be communicated and will only be communicated or caused to be communicated in the United Kingdom in circumstances in which section
21(1) of FSMA does not apply to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">In the United Kingdom, this document is being distributed only to,
and is directed at, persons (i) who have professional experience in matters relating to investments falling within Article 19(5) (investment
professionals) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (&ldquo;FPO&rdquo;), (ii) who fall within
the categories of persons referred to in Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the
FPO or (iii) to whom it may otherwise be lawfully communicated (together &ldquo;relevant persons&rdquo;). The investments to which this
document relates are available only to, and any invitation, offer or agreement to purchase will be engaged in only with, relevant persons.
Any person who is not a relevant person should not act or rely on this document or any of its contents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Pursuant to section 3A.3 of National Instrument 33-105 Underwriting
Conflicts, or NI 33-105, the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter
conflicts of interest in connection with this Offering.</P>


<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif;   text-transform: uppercase; letter-spacing: 0.6pt; text-align: center"><A NAME="a_014"></A>LEGAL
MATTERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Blank Rome LLP, New York, New York, will pass upon the validity
of the securities offered by this prospectus and certain other legal matters. Sullivan &amp; Worcester LLP, New York, New York, is acting
as legal counsel to the underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">As of the date of this prospectus, an attorney of Blank Rome LLP
beneficially owns Common Stock and securities exercisable to purchase shares of our Common Stock that represent less than 1% of our outstanding
shares of Common Stock.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;   text-transform: uppercase; letter-spacing: 0.6pt; text-align: center"><A NAME="a_015"></A>EXPERTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The consolidated financial statements of Scorpius Holdings, Inc.
(the Company) as of December&nbsp;31, 2023 and 2022 and for the years then ended, incorporated by reference in this prospectus and in
the registration statement have been so incorporated in reliance on the report of BDO USA, P.C., an independent registered public accounting
firm given on the authority of said firm as experts in accounting and auditing. The report on the consolidated financial statements contains
an explanatory paragraph regarding the Company&rsquo;s ability to continue as a going concern.</P>


<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif;   text-transform: uppercase; letter-spacing: 0.6pt; text-align: center"><A NAME="a_016"></A>WHERE
YOU CAN FIND MORE INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We have filed with the SEC a registration statement on Form S-1
under the Securities Act with respect to the securities offered hereby. This prospectus, which constitutes a part of the registration
statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed with the
registration statement. For further information about us and the securities offered hereby, we refer you to the registration statement
and the exhibits filed with the registration statement. Statements contained in this prospectus regarding the contents of any contract
or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement
is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration
statement. The SEC also maintains an internet website that contains reports, proxy statements and other information about registrants,
like us, that file electronically with the SEC. The address of that website is <I>www.sec.gov</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We are required to file periodic reports, proxy statements, and
other information with the SEC pursuant to the Exchange Act. These reports, proxy statements, and other information will be available
on the website of the SEC referred to above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We also maintain a website at <I>www.scorpiusbiologics.com</I>,
through which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with,
or furnished to, the SEC. Information contained on or accessed through our website is not a part of this prospectus and the inclusion
of our website address in this prospectus is an inactive textual reference only.&nbsp;</P>


<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif;   text-transform: uppercase; letter-spacing: 0.6pt; text-align: center"><A NAME="a_017"></A>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The SEC allows us to incorporate by reference information from other
documents that we file with it, which means that we can disclose important information to you by referring you to those documents. The
information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information
incorporated by reference that we filed with the SEC prior to the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incorporate by reference into this prospectus and the registration statement of which this prospectus is a part the information or documents
listed below that we have filed with the SEC (Commission File No. 001-35994):</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000155837024005902/scpx-20231231x10k.htm" STYLE="-sec-extract: exhibit">Form 10-K</A> for the fiscal December 31, 2023, filed with the SEC on April
                                            26, 2024;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            Quarterly Reports on Form 10-Q for the quarter ended <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000155837024008693/scpx-20240331x10q.htm" STYLE="-sec-extract: exhibit">March 31, 2024</A>, filed with the SEC on
                                            May 28, 2024, for the quarter ended <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000155837024012376/scpx-20240630x10q.htm" STYLE="-sec-extract: exhibit">June&nbsp;30, 2024</A>, filed with the SEC on August&nbsp;19,
                                            2024, and for the quarter ended <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000155837024015721/scpx-20240930x10q.htm" STYLE="-sec-extract: exhibit">September&nbsp;30, 2024</A>, filed with the SEC on November&nbsp;14,
                                            2024;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            Current Reports on Form 8-K filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000037/nhwk_8k.htm" STYLE="-sec-extract: exhibit">January 8, 2024</A> (other than information
                                            furnished under Item 7.01 and exhibits related thereto), <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000060/nhwk_8k.htm" STYLE="-sec-extract: exhibit">January 11, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000065/nhwk_8k.htm" STYLE="-sec-extract: exhibit">January 16, 2024</A>
                                            (other than information furnished under Item 7.01 and exhibits related thereto), <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000103/nhwk_8k.htm" STYLE="-sec-extract: exhibit">January
                                            22, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000128/nhwk_8k.htm" STYLE="-sec-extract: exhibit">January 26, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000145/nhwk_8k.htm" STYLE="-sec-extract: exhibit">January 30, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000175/scpx_8knc.htm" STYLE="-sec-extract: exhibit">February 6, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000359/scpx_8k.htm" STYLE="-sec-extract: exhibit">March 11, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000367/scpx_8k.htm" STYLE="-sec-extract: exhibit">March 13,
                                            2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000581/scpx_8k.htm" STYLE="-sec-extract: exhibit">April 22, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000617/scpx_8k.htm" STYLE="-sec-extract: exhibit">April 30, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000635/scpx_8k.htm" STYLE="-sec-extract: exhibit">May 2, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000767/scpx_8k.htm" STYLE="-sec-extract: exhibit">May 16, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000155335024000038/scpx_8k.htm" STYLE="-sec-extract: exhibit">May 22, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000812/scpx_8k.htm" STYLE="-sec-extract: exhibit">May 24, 2024</A>,
                                            <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000155837024008704/scpx-20240529x8k.htm" STYLE="-sec-extract: exhibit">May 29, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000824/scpx_8k.htm" STYLE="-sec-extract: exhibit">May 30, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000891/scpx_8k.htm" STYLE="-sec-extract: exhibit">June 17, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324001071/scpx_8k.htm" STYLE="-sec-extract: exhibit">July 18, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324001121/scpx_8k.htm" STYLE="-sec-extract: exhibit">July 30, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324001136/scpx_8k.htm" STYLE="-sec-extract: exhibit">July 31, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324001194/scpx_8k.htm" STYLE="-sec-extract: exhibit">August&nbsp;9,
                                            2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324001282/scpx_8k.htm" STYLE="-sec-extract: exhibit">August 19, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324001323/scpx_8k.htm" STYLE="-sec-extract: exhibit">August&nbsp;26, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324001654/scpx_8k.htm" STYLE="-sec-extract: exhibit">December&nbsp;3, 2024</A>,  <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324001666/scpx_8k.htm" STYLE="-sec-extract: exhibit">December&nbsp;6,
                                            2024</A>, and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1476963/000107997324001779/scpx_8k.htm">December&nbsp;27, 2024</A>;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our definitive proxy
                                                                                                                                                     statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000903/scpx_def14a.htm" STYLE="-sec-extract: exhibit">Schedule
                                                                                                                                                     14A</A>, filed with the SEC on June 17, 2024 and definitive proxy on <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324001744/scpx_def14a.htm" STYLE="-sec-extract: exhibit">Schedule 14A</A>, filed with the SEC on December 20, 2024</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            description of our Common Stock and our common stock purchase rights is set forth in our
                                            registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000155335022000099/htbx_8a.htm" STYLE="-sec-extract: exhibit">Form 8-A</A> filed with the SEC on February 4, 2022, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000155335022000214/htbx_8a.htm" STYLE="-sec-extract: exhibit">Form 8-A/A (Amendment
                                            No. 1)</A> filed on March 11, 2022, <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000155335023000164/htbx_8a.htm" STYLE="-sec-extract: exhibit">Form 8-A/A (Amendment No. 2)</A> filed on March 13, 2023, and
                                            <A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000369/scpx_8a.htm" STYLE="-sec-extract: exhibit">Form 8-A/A (Amendment No. 3)</A> filed on March 13, 2024 as updated by the description of our
                                            Common Stock filed as<A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000155837024005902/scpx-20231231xex4d14.htm" STYLE="-sec-extract: exhibit"> Exhibit 4.14</A> to our Annual Report on Form 10-K for the year ended December
                                            31, 2023 filed with the SEC on April 26, 2024, including any amendments or reports filed
                                            for the purpose of updating such description.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt/0.05pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We also incorporate by reference any future filings (other than
current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items unless
such Form 8-K expressly provides to the contrary) made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act,
including those made (i) on or after the date of the initial filing of the registration statement of which this prospectus forms a part
and prior to effectiveness of such registration statement, and (ii) on or after the date of this prospectus but prior to the termination
of the offering (i.e., until the earlier of the date on which all of the securities registered hereunder have been sold or the registration
statement of which this prospectus forms a part has been withdrawn). Information in such future filings updates and supplements the information
provided in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information
in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent
that statements in the later filed document modify or replace such earlier statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We will furnish without charge to each person, including any beneficial
owner, to whom a prospectus is delivered, upon written or oral request, a copy of any or all of the documents incorporated by reference
into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such
documents. You should direct any requests for documents to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">Scorpius Holdings, Inc.<BR>
627 Davis Drive, Suite 300<BR>
Morrisville, North Carolina 27560<BR>
Telephone (610) 727-4597<BR>
Attention: Corporate Secretary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">You may also access these documents, free of charge, on the SEC&rsquo;s
website at <I>www.sec.gov</I> or on our website at <I>https://scorpiusbiologics.com/investors/sec-filings</I>. The information contained
in, or that can be accessed through, our website is not incorporated by reference into, and is not part of, this prospectus or any accompanying
prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">In accordance with Rule 412 of the Securities Act, any statement
contained in a document incorporated by reference herein shall be deemed modified or superseded to the extent that a statement contained
herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes
such statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">You should rely only on information contained in, or incorporated
by reference into, this prospectus and any prospectus supplement. We have not authorized anyone to provide you with information different
from that contained in this prospectus or incorporated by reference into this prospectus. We are not making offers to sell the securities
in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation
is not qualified to do so or to anyone to whom it is unlawful to make such an offer or solicitation.</P>


<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Up to 29,411,764&nbsp;Shares
of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Up to 29,411,764&nbsp;Pre-Funded
Warrants to purchase up to 29,411,764 Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Up to 29,411,764&nbsp;Shares
of Common Stock Underlying such Pre-Funded Warrants</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 38.85pt 0 0; text-align: center"><FONT STYLE="font-size: 14pt"><B><IMG SRC="image_006.jpg" ALT="A logo of a dinosaur&#10;&#10;Description automatically generated" STYLE="height: 148px; width: 230px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 30pt 0 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>Scorpius Holdings,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 24pt 0 0; text-align: center"><B>____________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6.45pt 0 0; text-align: center"><B>PRELIMINARY PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>____________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 48.6pt 0 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>ThinkEquity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 48.6pt 0 0; text-align: center; text-indent: 16.2pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;2024&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 24pt 0 12pt">Through and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(the 25<SUP>th</SUP>&nbsp;day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not
participating in this Offering, may be required to deliver a prospectus. This is in addition to a dealer&rsquo;s obligation to deliver
a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.</P>


<!-- Field: Page; Sequence: 55; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif;   text-transform: uppercase; letter-spacing: 0.6pt; text-align: center">PART
II &mdash; INFORMATION NOT REQUIRED IN PROSPECTUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Item 13. Other Expenses of Issuance and Distribution</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The following table sets forth the expenses in connection with this
registration statement. All of such expenses are estimates, other than the filing fees payable to the Securities and Exchange Commission
and to FINRA.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 12pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>Amount to be paid</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 83%; text-align: left">SEC registration fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">1,871</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">FINRA filing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,333</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Miscellaneous expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">70,796</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">400,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Item 14. Indemnification of Directors and Officers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Section 145 of the Delaware General Corporation Law (the &ldquo;DGCL&rdquo;)
empowers a corporation to indemnify its directors and officers and to purchase insurance with respect to liability arising out of their
capacity or status as directors and officers, provided that the person acted in good faith and in a manner the person reasonably believed
to be in our best interests, and, with respect to any criminal action, had no reasonable cause to believe the person&rsquo;s actions were
unlawful. The DGCL further provides that the indemnification permitted thereunder shall not be deemed exclusive of any other rights to
which the directors and officers may be entitled under the corporation&rsquo;s bylaws, any agreement, a vote of stockholders or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Section 102(b)(7) of the DGCL permits a corporation to provide in
its certificate of incorporation that a director or officer of the corporation shall not be personally liable to the corporation or its
stockholders for monetary damages for breach of fiduciary duty as a director or officer, except (i)&nbsp;for any breach of the director&rsquo;s
or officer&rsquo;s duty of loyalty to the corporation or its stockholders; (ii)&nbsp;for acts or omissions not in good faith or which
involve intentional misconduct or a knowing violation of law; (iii)&nbsp;for any transaction from which the director or officer derived
an improper personal benefit; (iv)&nbsp;a director for payments of unlawful dividends or unlawful stock repurchases or redemptions; or
(v)&nbsp;an officer in any action by or in the right of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Our Bylaws provide that we will indemnify our directors and officers
to the fullest extent permitted by law. Our Bylaws also provide that we are obligated to advance expenses incurred by a present or former
director or officer in advance of the final disposition of any action or proceeding. In addition, as permitted by Delaware law, our Certificate
of Incorporation includes provisions that eliminate the personal liability of our directors and officers for monetary damages resulting
from breaches of certain fiduciary duties as a director or officer, as appplicable, except to the extent such an exemption from liability
thereof is not permitted under the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">We have entered into indemnification agreements with each of our
directors. These agreements will require us to indemnify these individuals to the fullest extent permitted under Delaware law against
liabilities that may arise by reason of their service to us and to advance expenses incurred as a result of any proceeding against them
as to which they could be indemnified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The Registrant has an insurance policy in place that covers its
officers and directors with respect to certain liabilities, including liabilities arising under the Securities Act or otherwise.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  "></P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif">Item 15. Recent Sales of Unregistered Securities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The Company has not issued unregistered securities to any person
within the last three years other than:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">the issuance to Elusys Holdings, Inc. on January 26, 2024 of a convertible promissory note in the aggregate
amount of $2,250,000 (the &ldquo;Original Convertible Note&rdquo;), the conversion of which was subject to both Elusys&rsquo; election
and obtaining stockholder approval of the issuance of shares of our Common Stock upon such conversion. The Original Convertible Note bore
interest at a rate of 1% per annum, matured on the one-year anniversary of its issuance and was convertible into shares of our Common
Stock at the option of Elusys only if stockholder approval of the issuance of such shares of Common Stock issuable upon conversion of
the Original Convertible Note was obtained prior to the maturity date, which approval has been obtained. The conversion price of the Original
Convertible Note was equal to 110% of the volume weighted average price (VWAP) of Common Stock for the seven trading days prior to December
11, 2023 which was $0.39109;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">the issuance to Elusys Holdings, Inc., on May 1, 2024, of a 1% non-convertible promissory note, as amended,
due July 31, 2024 in the principal amount of $750,000 (the &ldquo;New Note&rdquo;) for $750,000; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">the issuance to Elusys Holdings, Inc., on May 1, 2024, of an amended and restated 1% convertible promissory
note in the principal amount of $2,250,000 with a maturity date of September 1, 2025 (the &ldquo;Restated Note&rdquo;) in exchange for
the Original Convertible Note, the conversion of which is subject to both Elusys&rsquo; election and obtaining stockholder approval of
the issuance of shares of our Common Stock upon such conversion, which approval has been obtained. The conversion price, as amended, was
$0.11, which was 110% of the public offering price per share of the shares of Common Stock sold in our May 2024 public offering, which
conversion price was increased to $22.00 as a result of the 2024 Reverse Stock Split; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">the issuance to an institutional investor, on November 27, 2024, of the November 2024 Note in the principal
amount of Two Hundred Twenty-Five Thousand Dollars ($225,000), which accrues interest at the rate of 5.0% per annum and matures on the
earlier of: (i) December 15, 2024; (ii) the consummation of a Corporate Event (as such term is defined in the November 2024 Note); or
(iii) when, upon or after the occurrence of an event of default under the November 2024 Note; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">the issuance to certain institutional investors on December&nbsp;6, 2024 of the Secured Convertible
Notes, convertible into up to an aggregate of 34,007,778 shares of Common Stock, and the December Warrants to purchase up to an aggregate
of 13,388,889 shares of Common Stock, for an aggregate purchase price of $12,050,000. The Secured Convertible Notes mature on the third
anniversary of their date of issuance, unless prior thereto there is an event of default, and bear interest at a rate of 9% per annum
payable in cash on the first business day of each fiscal quarter beginning January&nbsp;2, 2025. The Secured Convertible Notes are convertible,
at the option of the holder, at any time, into a number of shares of Common Stock equal to the principal amount of the Secured Convertible
Notes, plus all accrued and unpaid interest at a conversion price equal to $0.50, subject to adjustment for any stock splits, stock dividends,
recapitalizations and similar events and subject to an Exchange Cap (as defined therein) and other limitations.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The Original Convertible Note, the New Note, the November 2024 Note,
the Secured Convertible Notes, the Warrants and the shares of Common Stock that may be issued under the Notes and Warrants were offered
and sold in transactions exempt from registration under Section&nbsp;4(a)(2) of the Securities Act and the Restated Note and the shares
of Common Stock that may be issued under the Restated Note, respectively, were offered and sold in transactions exempt from registration
under the Securities Act in reliance on Section&nbsp;3(a)(9) thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The recipients of the securities in each of these transactions represented
their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution
thereof, and appropriate legends were placed upon the stock certificates issued in these transactions. All recipients had adequate access,
through their employment or other relationship with us or through other access to information provided by us, to information about us.
The sales of these securities were made without any general solicitation or advertising.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  "></P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif">Item 16. Exhibits and Financial Statement Schedules</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The exhibits to this registration statement are listed in the Exhibit
Index to this registration statement, which immediately precedes the signature page and which Exhibit Index is hereby incorporated by
reference.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif;  ">Item 17. Undertakings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The undersigned registrant hereby undertakes:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD><FONT STYLE="font-size: 10pt">To file, during any period in which offers or sales are being made, a post-effective amendment to this
registration statement:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">i.</FONT></TD><TD><FONT STYLE="font-size: 10pt">to include any prospectus required by Section 10(a)(3) of the Securities Act;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">ii.</FONT></TD><TD><FONT STYLE="font-size: 10pt">to reflect in the prospectus any facts or events arising after the effective date of this registration
statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change
in the information set forth in this registration statement (notwithstanding the foregoing, any increase or decrease in volume of securities
offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or
high end of the estimated maximum offering range may be reflected in the form of a prospectus filed with the Commission pursuant to Rule
424(b) under the Securities Act if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum
aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement);
and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">iii.</FONT></TD><TD><FONT STYLE="font-size: 10pt">to include any material information with respect to the plan of distribution not previously disclosed
in this registration statement or any material change to such information in this registration statement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in">provided, however, that subparagraphs (i), (ii) and (iii)
do not apply if the information required to be included in a post-effective amendment by those subparagraphs is contained in reports filed
with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934,
that are incorporated by reference into this registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b)
that is part of the registration statement.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD><FONT STYLE="font-size: 10pt">That, for the purpose of determining any liability under the Securities Act, each such post-effective
amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD><FONT STYLE="font-size: 10pt">To remove from registration, by means of a post-effective amendment, any of the securities being registered
which remain unsold at the termination of the offering.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD><FONT STYLE="font-size: 10pt">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each
prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements
relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration
statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or
prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the
registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale
prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of
the registration statement or made in any such document immediately prior to such date of first use.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(5)</FONT></TD><TD><FONT STYLE="font-size: 10pt">That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to
any purchaser in the initial distribution of the securities:<BR>
<BR>
The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration
statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to
such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will
be considered to offer or sell such securities to such purchaser:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">i.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required
to be filed pursuant to Rule 424 (&sect; 230.424 of this chapter);</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">ii.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant
or used or referred to by the undersigned registrant;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">iii.</FONT></TD><TD><FONT STYLE="font-size: 10pt">The portion of any other free writing prospectus relating to the offering containing material information
about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">iv.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(6)</FONT></TD><TD><FONT STYLE="font-size: 10pt">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors,
officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised
that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by a Registrant of expenses incurred or
paid by a director, officer or controlling person of a Registrant in the successful defense of any action, suit or proceeding) is asserted
by such director, officer or controlling person in connection with the securities being registered, that Registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question
whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication
of such issue.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(7)</FONT></TD><TD><FONT STYLE="font-size: 10pt">For purposes of determining any liability under the Securities Act of 1933, the information omitted
from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus
filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration
statement as of the time it was declared effective.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(8)</FONT></TD><TD><FONT STYLE="font-size: 10pt">For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment
that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and
the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(9)</FONT></TD><TD><FONT STYLE="font-size: 10pt">For purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&rsquo;s
annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of
an employee benefit plan&rsquo;s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated
by reference into the registration statement shall be deemed to be a new registration statement relating to the securities offered therein,
and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.&nbsp;</FONT></TD></TR></TABLE>


<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif;   text-transform: uppercase; letter-spacing: 0.6pt; text-align: center">EXHIBIT
INDEX</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The exhibits listed in the accompanying Exhibit Index are filed
or incorporated by reference as part of this registration statement.</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1*</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex1x1.htm">Form of Underwriting Agreement by and between Scorpius Holdings, Inc. and ThinkEquity LLC</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000155335021001182/ex2x1.htm">Merger
    Agreement, dated December 20, 2021, by and among the Registrant, Heat Acquisition Sub 1, Inc. and Elusys Therapeutics, Inc. (incorporated
    by reference to Exhibit 2.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 21, 2021
    (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000155837023019741/nhwk-20231211xex2d1.htm">Asset
    and Equity Interests Purchase Agreement by and between the Registrant and Elusys Holdings Inc., dated as December 12, 2023 (incorporated
    by reference to Exhibit 2.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 12, 2023
    (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335013000103/heat_ex3z5.htm">Third
    Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.5 to the Registration Statement on Form&nbsp;S-1
    with the Securities and Exchange Commission on May&nbsp;6, 2013 (File No.&nbsp;333-188365))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335013000237/heat_ex3z6.htm">Certificate
    of Amendment to the Third Amended and Restated Certificate of Incorporation filed on May&nbsp;29, 2013 (incorporated by reference
    to Exhibit 3.6 to the Registration Statement on Form&nbsp;S-1 with the Securities and Exchange Commission on May&nbsp;30, 2013 (File
    No.&nbsp;333-188365))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335017000845/htbx_ex3z1.htm">Certificate
    of Amendment to the Third Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Current
    Report on Form 8-K filed with the Securities and Exchange Commission on July&nbsp;17, 2017 (File No.&nbsp;001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/0001476963/000155335018000059/htbx_ex3z1.htm">Certificate
    of Amendment to the Third Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Current
    Report on Form 8-K filed with the Securities and Exchange Commission on January&nbsp;19, 2018 (File No.&nbsp;001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335020000232/htbx_ex3z1.htm">Certificate
    of Amendment to the Third Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Current
    Report on Form 8-K filed with the Securities and Exchange Commission March 23, 2020 (File No. 001 -35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335019001070/htbx_ex3z1.htm">Amended
    and Restated Bylaws, dated October 17, 2019 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with
    the Securities and Exchange Commission on October 18, 2019 (File No.&nbsp;001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335020001092/htbx_ex3z1.htm">Certificate
    of Amendment to the Third Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Current
    Report on Form 8-K filed with the Securities and Exchange Commission on December 10, 2020 (File No. 001 -35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335022000385/nhwk_ex3z1.htm">Certificate
    of Amendment to the Third Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Current
    Report on Form 8-K filed with the Securities and Exchange Commission on May 3, 2022 (File No. 001 -35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335022000385/nhwk_ex3z2.htm">Second
    Amended and Restated Bylaws, dated May 3, 2022 (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed
    with the Securities and Exchange Commission on May 3,2022 (File No. 001 -35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000107997324000175/ex3x1.htm">Certificate
    of Amendment to Certificate of Incorporation to the Third Amended and Restated Certificate of Incorporation, dated February 5, 2024
    (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on
    February 6, 2024 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.11</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000107997324001071/ex3x1.htm">Certificate
    of Amendment of the Company&rsquo;s Third Amended and Restated Certificate of Incorporation, filed with the Secretary of State of
    Delaware on July 17, 2024 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Securities and
    Exchange Commission on July 18, 2024 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335013000103/heat_ex4z1.htm">2009
    Stock Incentive Plan (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form&nbsp;S-1 with the Securities
    and Exchange Commission on May&nbsp;6, 2013 (File No.&nbsp;333-188365))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335013000103/heat_ex4z2.htm">First
    Amendment of the 2009 Stock Incentive Plan (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form&nbsp;S-1
    with the Securities and Exchange Commission on May&nbsp;6, 2013 (File No.&nbsp;333-188365))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335013000103/heat_ex4z3.htm">Second
    Amendment of the 2009 Stock Incentive Plan (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form&nbsp;S-1
    with the Securities and Exchange Commission on May&nbsp;6, 2013 (File No.&nbsp;333-188365))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335013000103/heat_ex4z4.htm">Third
    Amendment of the 2009 Stock Incentive Plan (incorporated by reference to Exhibit 4.4to the Registration Statement on Form&nbsp;S-1
    with the Securities and Exchange Commission on May&nbsp;6, 2013 (File No.&nbsp;333-188365))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335013000103/heat_ex4z5.htm">Fourth
    Amendment of the 2009 Stock Incentive Plan (incorporated by reference to Exhibit 4.5 to the Registration Statement on Form&nbsp;S-1
    with the Securities and Exchange Commission on May 6, 2013 (File No. 333-188365))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335013000103/heat_ex4z8.htm">Specimen
    Common Stock Certificate of Heat Biologics,&nbsp;Inc. (incorporated by reference to Exhibit 4.8 to the Registration Statement on
    Form&nbsp;S-1 with the Securities and Exchange Commission on May&nbsp;6, 2013 (File No.&nbsp;333-188365))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000155335014000651/htbx_ex4z1.htm">2014
    Stock Incentive Plan (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form&nbsp;S-8 with the Securities
    and Exchange Commission on June&nbsp;13, 2014 (File No.&nbsp;333-196763))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335015000648/htbx_14a.htm">Amended
    and Restated Heat Biologics,&nbsp;Inc. 2014 Stock Incentive Plan (incorporated by reference to Appendix A to the Definitive Proxy
    Statement on Schedule 14A filed with the Securities and Exchange Commission on June&nbsp;22, 2015))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335017000828/htbx_ex4z1.htm">2017
    Stock Incentive Plan (incorporated by reference as Exhibit 4.1 to the Registration Statement on Form&nbsp;S-8 with the Securities
    and Exchange Commission on July&nbsp;11, 2017 (File No.&nbsp;333-219238))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335018000199/htbx_ex4z1.htm">Rights
    Agreement between Heat Biologics,&nbsp;Inc. and Continental Stock Transfer&nbsp;&amp; Trust Company dated March&nbsp;11, 2018 (incorporated
    by reference to Exhibit 4.1 to the Current Report on Form&nbsp;8-K with the Securities and Exchange Commission on March&nbsp;12,
    2018 (File No.&nbsp;001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335018001095/htbx_ex4z1.htm">2018
    Stock Incentive Plan ((incorporated by reference to Exhibit 4.1 to the Registration Statement on Form&nbsp;S-8 with the Securities
    and Exchange Commission on October&nbsp;4, 2018 (File No.&nbsp;333-219238))</A></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Value: 5; Name: PageNo -->5<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335019000202/htbx_ex4z2.htm">Amendment
    No.&nbsp;1 to Rights Plan (incorporated by reference to Exhibit 4.2 to the Current Report on Form&nbsp;8-K filed with the Securities
    and Exchange Commission on March&nbsp;12, 2019 (File No.&nbsp;001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000155335020000213/htbx_ex4z3.htm">Amendment
    No. 2 to the Rights Agreement dated as of March 10, 2020 to the Rights Agreement dated March 11, 2018, as amended by Amendment No.
    1 thereto, dated as of March 8, 2019, by and between Heat Biologics, Inc. and Continental Stock Transfer &amp; Trust Company, as
    rights agent (incorporated by reference to Exhibit 4.3 to the Form 8-A/A filed with the Securities and Exchange Commission on March
    13, 2020 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/0001476963/000155335021000177/htbx_ex4z4.htm">Amendment
    No. 3 to the Rights Agreement dated as of March 8, 2021 to the Rights Agreement dated March 11, 2018, as amended by Amendment No.
    1 thereto, dated as of March 8, 2019, and Amendment No. 2 thereto, dated as of March 10, 2020, by and between Heat Biologics, Inc.
    and Continental Stock Transfer &amp; Trust Company, as rights agent (incorporated by reference to Exhibit 4.1 to the Form 8-K filed
    with the Securities and Exchange Commission on March 12, 2021 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335021000632/htbx_14a.htm">Heat
    Biologics, Inc. 2021 Subsidiaries Stock Incentive Plan&nbsp;(incorporated by reference as Exhibit B to the Heat Biologics, Inc. Definitive
    Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on August 3, 2021 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335022000212/htbx_ex4z5.htm">Amendment
    No. 4 to the Rights Agreement dated as of March 8, 2021 to the Rights Agreement dated March 11, 2018, as amended by Amendment No.
    1 thereto, dated as of March 8, 2019, Amendment No. 2 thereto, dated as of March 10, 2020, and Amendment No. 3 thereto dated as of
    March 8, 2021 by and between Heat Biologics, Inc. and Continental Stock Transfer &amp; Trust Company, as rights agent (incorporated
    by reference to Exhibit 4.5 to the Form 8-K filed with the Securities and Exchange Commission on March 11, 2022 (File No. 001-35994)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335023000162/nhwk_ex4z6.htm">Amendment
    No. 5 to the Rights Agreement dated as of March 11, 2023 to the Rights Agreement dated March 11, 2018, as amended by Amendment No.
    1 thereto, dated as of March 8, 2019, Amendment No. 2 thereto, dated March 10, 2020, Amendment No. 3 thereto, dated March 8, 2021,
    and Amendment No. 4 thereto, dated March 11, 2022, by and between the Registrant and Continental Stock Transfer &amp; Trust Company,
    as rights agent (incorporated by reference to Exhibit 4.6 to the Form 8-K filed with the Securities and Exchange Commission on March
    13, 2023 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155837023019741/nhwk-20231211xex4d7.htm">Amendment
    No. 6 to the Rights Agreement dated as of December 11, 2023 to the Rights Agreement dated March 11, 2018, as amended by Amendment
    No. 1 thereto, dated as of March 8, 2019, Amendment No. 2 thereto, dated March 10, 2020, Amendment No. 3 thereto, dated March 8,
    2021, Amendment No. 4 thereto, dated March 11, 2022, and Amendment No. 5 thereto, dated March 11, 2023, by and between the Registrant
    and Continental Stock Transfer &amp; Trust Company, as rights agent (incorporated by reference to Exhibit 4.7 to the Current Report
    on Form 8-K filed with the Securities and Exchange Commission on December 12, 2023 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000367/ex4x8.htm">Amendment
    No. 7 to Rights Agreement (incorporated by reference to Exhibit 4.8 to the Current Report on Form 8-K filed with the Securities and
    Exchange Commission on March 13, 2024 (File No.&nbsp;001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000107997324000145/ex4x1.htm">Convertible
    Note in the principal amount of &nbsp;$2,250,000 issued to Elusys Holdings Inc. (incorporated by reference to Exhibit 4.1 to the
    Current Report on Form 8-K filed with the Securities and Exchange Commission on January 30, 2024 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.21</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000635/ex4x1.htm">Note,
    dated May 1, 2024, in the principal amount of $750,000 (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K
    filed with the Securities and Exchange Commission on May 2, 2024 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000635/ex4x2.htm">Amended
    and Restated Convertible Note, dated May 1, 2024 in the principal amount of $2,250,000 (incorporated by reference to Exhibit 4.2
    to the Current Report on Form 8-K filed with the Securities and Exchange Commission on May 2, 2024 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.23</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000107997324000767/ex4x1.htm">Form
    of Common Warrant incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Securities and Exchange
    Commission on May 16, 2024 (File No. 001-35994)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.24</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000107997324000767/ex4x2.htm">Form
    of Pre-Funded Warrant (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed with the Securities and Exchange
    Commission on May 16, 2024 (File No. 001-35994)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.25</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000107997324001071/ex4x1.htm">Amendment
    dated July 16, 2024 to Note dated May 1, 2024 (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with
    the Securities and Exchange Commission on July 18, 2024 (File No. 001-35994)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.26</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000107997324001282/ex4x1.htm">Form
    of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Securities and Exchange
    Commission on August 19, 2024 (File No. 001-35994)</A><FONT><U>)</U></FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.27</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324001654/ex4x1.htm" STYLE="-sec-extract: exhibit">Form
    of Promissory Note (incorporated by reference to Exhibit&nbsp;4.1 to the Current Report on Form 8-K filed with the Securities and
    Exchange Commission on December&nbsp;3, 2024 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.28</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324001666/ex4x1.htm" STYLE="-sec-extract: exhibit">Form
    of Senior Secured Convertible Note (incorporated by reference to Exhibit&nbsp;4.1 to the Current Report on Form 8-K filed with the
    Securities and Exchange Commission on December&nbsp;6, 2024 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.29</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324001666/ex4x2.htm" STYLE="-sec-extract: exhibit">Form
    of Warrant (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission
    on December 6, 2024 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.30*</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex4x30.htm">Form of Pre-Funded Warrant</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.31*</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex4x31.htm">Form of Representative&rsquo;s Warrant</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex5x1.htm">Opinion of Blank Rome LLP</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335015000757/htbx_ex10z4.htm">Form&nbsp;of
    Incentive Stock Option Agreement under the 2014 Stock Incentive Plan, as amended (incorporated by reference to Exhibit 10.4 to the
    Current Report on Form&nbsp;8-K with the Securities and Exchange Commission on July&nbsp;27, 2015 (File No.&nbsp;001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335015000757/htbx_ex10z5.htm">Form&nbsp;of
    Non-Statutory Stock Option Agreement under the 2014 Stock Incentive Plan, as amended (incorporated by reference to Exhibit 10.5 to
    the Current Report on Form&nbsp;8-K with the Securities and Exchange Commission on July&nbsp;27, 2015 (File No.&nbsp;001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335016002361/htbx_ex10z2.htm">Form&nbsp;of
    Indemnification Agreement by and between Heat Biologics,&nbsp;Inc. and its directors and officers (incorporated by reference to Exhibit
    10.2 to the Quarterly Report on Form&nbsp;10-Q with the Securities and Exchange Commission on August&nbsp;15, 2016 (File No.&nbsp;001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335017000017/htbx_ex10z4.htm">Form&nbsp;of
    Restricted Stock Unit Award Agreement (incorporated by reference to Exhibit 10.4 to the Current Report on Form&nbsp;8-K with the
    Securities and Exchange Commission on January&nbsp;4, 2017 (File No.&nbsp;001-35994))</A></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335018000174/htbx_ex10z77.htm">Form&nbsp;of
    Incentive Stock Option Agreement under the 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.77 to the Heat Biologics,&nbsp;Inc.&rsquo;s
    Annual Report on Form&nbsp;10-K filed with the Securities and Exchange Commission on March&nbsp;2, 2018 (File No.&nbsp;001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335018000174/htbx_ex10z78.htm">Form&nbsp;of
    Non-Statutory Stock Option Agreement under the 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.78 to the Heat
    Biologics,&nbsp;Inc.&rsquo;s Annual Report on Form&nbsp;10-K filed with the Securities and Exchange Commission on March&nbsp;2, 2018
    (File No.&nbsp;001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335018000174/htbx_ex10z79.htm">Form&nbsp;of
    Restricted Stock Unit Award Agreement under the 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.79 to the Heat
    Biologics,&nbsp;Inc.&rsquo;s Annual Report on Form&nbsp;10-K filed with the Securities and Exchange Commission on March&nbsp;2, 2018
    (File No.&nbsp;001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000155335018001095/htbx_ex4z2.htm">Form&nbsp;of
    Incentive Stock Option Agreement under the 2018 Stock Incentive Plan (incorporated by reference to Exhibit 4.2 to the Registration
    Statement on Form&nbsp;S-8 with the Securities and Exchange Commission on October&nbsp;4, 2018 (File No.&nbsp;333-219238))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335018001095/htbx_ex4z3.htm">Form&nbsp;of
    Non-Statutory Stock Option Agreement under the 2018 Stock Incentive Plan (incorporated by reference to Exhibit 4.3 to the Registration
    Statement on Form&nbsp;S-8 with the Securities and Exchange Commission on October&nbsp;4, 2018 (File No.&nbsp;333-219238))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335018001095/htbx_ex4z4.htm">Form&nbsp;of
    Notice of Award under the 2018 Stock Incentive Plan (incorporated by reference to Exhibit 4.4 to the Registration Statement on Form&nbsp;S-8
    with the Securities and Exchange Commission on October&nbsp;4, 2018 (File No.&nbsp;333-219238))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335018001095/htbx_ex4z5.htm">Form&nbsp;of
    Restricted Stock Agreement under the 2018 Stock Incentive Plan (incorporated by reference to Exhibit 4.5 to the Registration Statement
    on Form&nbsp;S-8 with the Securities and Exchange Commission on October&nbsp;4, 2018 (File No.&nbsp;333-219238))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335019000005/htbx_ex10z2.htm">Heat
    Biologics,&nbsp;Inc. Form&nbsp;of Restricted Stock Agreement (incorporated by reference to Exhibit 10.2 to the Current Report on
    Form&nbsp;8-K filed with the Securities and Exchange Commission on January&nbsp;3, 2019 (File No.&nbsp;001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335019000622/htbx_14a.htm">Amendment
    No. 1 to the Heat Biologics, Inc. 2018 Stock Incentive Plan (incorporated by reference to Appendix A to the Definitive Proxy Statement
    on Schedule 14A filed with the Securities and Exchange Commission on June 4, 2019 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/0001476963/000155335020000008/htbx_ex10z4.htm">Form
    of Restricted Stock Agreement (incorporated by reference to Exhibit 10.4 to the Heat Biologics, Inc. Current Report on Form 8-K filed
    with the Securities and Exchange Commission on January 3, 2020 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335020000089/htbx_14a.htm">Amendment
    no. 2 to the Heat Biologics 2018 Stock Incentive Plan (incorporated by reference to Exhibit 4.3 to the Registration Statement on
    Form S-8 filed with the Securities and Exchange Commission on March 12, 2020)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/0001476963/000155335020000653/htbx_14a.htm">Amendment
    No. 3 to the Heat Biologics, Inc. 2018 Stock Incentive Plan (incorporated by reference to Appendix A to the Definitive Proxy Statement
    on Schedule 14A filed with the Securities and Exchange Commission on July 27, 2020)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/0001476963/000155335021000005/htbx_ex10z3.htm">Employment
    Agreement between Heat Biologics, Inc. and Jeffrey Wolf, dated as of January 4, 2021 (incorporated by reference to Exhibit 10.3 to
    the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 6, 2021 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/0001476963/000155335021000005/htbx_ex10z4.htm">Form
    of Restricted Stock Agreement (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed with the Securities
    and Exchange Commission on January 6, 2021 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335021000533/htbx_ex10z1.htm">Lease
    between Durham Keystone Tech 7, LLC and Heat Biologics, Inc. dated June 21, 2021 (incorporated by reference to Exhibit 10.1 to the
    Heat Biologics, Inc.&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 23, 2021 (File
    No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335021000634/htbx_ex10z2.htm">Form
    of Stock Option Agreement for the Heat Biologics 2021 Subsidiaries Stock Incentive Plan (incorporated by reference to Exhibit 10.2
    to the Current Report on Form 8-K filed with the Securities and Exchange Commission on August 3, 2021 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335021000634/htbx_ex10z3.htm">Form
    of Restricted Stock Purchase Agreement for the Heat Biologics 2021 Subsidiaries Stock Incentive Plan (incorporated by reference to
    Exhibit 10.3 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on August 3, 2021 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335021000632/htbx_14a.htm">Heat
    Biologics, Inc. 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit A to the Definitive Proxy Statement on Schedule
    A filed with the Securities and Exchange Commission on August 3, 2021 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335019000414/htbx_ex10z1.htm">Lease
    between Merchants Ice II, LLC and Heat Biologics, Inc. dated June October 5, 2021 (incorporated by reference to Exhibit 10.1 to the
    Heat Biologics, Inc.&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 7, 2021 (File
    No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335021001170/htbx_ex10z1.htm">Form
    of Amended and Restated Restricted Stock Agreement (incorporated by reference to Exhibit 10.1 to the Heat Biologics, Inc.&rsquo;s
    Current Report on Form 8-K filed with the Securities and Exchange Commission on December 15, 2021(File No.001-35994)</A><FONT><U>)</U></FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335021001170/htbx_ex10z2.htm">Employment
    Agreement effective as of January 1, 2022 by and between Heat Biologics, Inc. and William Ostrander (incorporated by reference to
    Exhibit 10.2 to the Heat Biologics, Inc.&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange Commission on
    December 15, 2021(File No.001-35994)</A><FONT><U>)</U></FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155837023005289/nhwk-20221231xex10d62.htm">Ordering
    Agreement between Lonza Sales AG and Elusys Therapeutics, Inc. (incorporated by reference to Exhibit 10.62 to the Heat Biologics,
    Inc.&rsquo;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2023(File No.001-35994)</A><FONT><U>)</U></FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155837023005289/nhwk-20221231xex10d63.htm">Ordering
    Agreement between Lonza Sales AG and Elusys Therapeutics, Inc. (incorporated by reference to Exhibit 10.63 to the Heat Biologics,
    Inc.&rsquo;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2023(File No.001-35994)</A><FONT><U>)</U></FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335022000006/htbx_10z1.htm">Form
    of New Incentive Stock Option Agreement under the 2018 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current
    Report on Form 8 K with the Securities and Exchange Commission on January 3, 2022 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335022000006/htbx_10z2.htm">Form
    of New Non-Statutory Stock Option Agreement under the 2018 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the
    Current Report on Form 8 K with the Securities and Exchange Commission on January 3, 2022 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335022000636/nhwk_14a.htm">Amendment
    No. 4 to the Heat Biologics, Inc. 2018 Stock Incentive Plan (incorporated by reference to Appendix A to the Definitive Proxy Statement
    on Schedule 14A filed with the Securities and Exchange Commission on July 28, 2022)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335022000636/nhwk_14a.htm">Amendment
    No. 4 to the Scorpius Holdings, Inc. 2021 Subsidiaries Stock Incentive Plan (incorporated by reference to Appendix A to the Definitive
    Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on July 28, 2022)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997322001526/ex10x2.htm">Amendment
    No. 1 to Employment Agreement between Scorpius Holdings, Inc. and Jeffrey Wolf, effective as of December 7, 2022 (incorporated by
    reference to Exhibit 10.2 to the Heat Biologics, Inc. Current Report on Form 8-K filed with the Securities and Exchange Commission
    on December 9, 2022 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997322001526/ex10x1.htm">Amendment
    No. 1 to Employment Agreement between Scorpius Holdings, Inc. and William Ostrander, effective as of December 7, 2022 (incorporated
    by reference to Exhibit 10.1 to the Heat Biologics, Inc. Current Report on Form 8-K filed with the Securities and Exchange Commission
    on December 9, 2022 (File No. 001-35994))</A></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335023000012/nhwk_ex10z1.htm">Lease
    between TPB Merchants Ice LLC and Scorpion Biologics, Inc. dated December 31, 2022 (incorporated by reference to Exhibit 10.1 to
    the Heat Biologics, Inc.&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 25, 2023
    (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155837023019741/nhwk-20231211xex10d1.htm">Amendment
    No. 2 to William Ostrander Employment Agreement with the Registrant, dated as of December 11, 2023 (incorporated by reference to
    Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 12, 2023 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000155837023019741/nhwk-20231211xex10d2.htm">Form
    of Shared Services Agreement between the Registrant and Elusys Holdings Inc. (incorporated by reference to Exhibit 10.2 to the Current
    Report on Form 8-K filed with the Securities and Exchange Commission on December 12, 2023 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000145/ex10x1.htm">Patent
    Rights Sale and Assignment Agreement between NightHawk Biosciences, Inc. and Kopfkino IP, LLC (incorporated by reference to Exhibit
    10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 30, 2024 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324000635/ex10x1.htm">Note
    Purchase Agreement, dated May 1, 2024 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the
    Securities and Exchange Commission on May 2, 2024 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000107997324001071/ex10x1.htm">Amendment
    No. 5 to Nighthawk Biosciences, Inc. 2018 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on
    Form 8-K filed with the Securities and Exchange Commission on July 18, 2024 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.40</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1476963/000107997324001136/scpx_8k.htm">Note
    Cancellation and Amendment to Asset and Equity Interests Purchase Agreement by and between the Registrant and Elusys Holdings Inc.,
    dated as July 30, 2024 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and
    Exchange Commission on July 31, 2024 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.41</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324001282/ex1x1.htm" STYLE="-sec-extract: exhibit">Underwriting
                                            Agreement, dated as of August 16, 2024, by and between Scorpius Holdings, Inc. and ThinkEquity
                                            LLC as Representative of the several Underwriters (incorporated by reference to Exhibit 1.1
                                            to the Current Report on Form 8-K filed with the Securities and Exchange Commission on August 19,
                                            2024 (File No. 001-35994))</A></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.42#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324001323/ex10x2.htm" STYLE="-sec-extract: exhibit">Amendment
    No. 2 to Jeffrey Wolf Employment Agreement with the Company dated as of August 23, 2024 (incorporated by reference to Exhibit 10.1
    to the Current Report on Form 8-K filed with the Securities and Exchange Commission on August&nbsp;26, 2024 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.43#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324001323/ex10x1.htm" STYLE="-sec-extract: exhibit">Amendment
    No. 3 to William Ostrander Employment Agreement with the Company dated as of August 23, 2024 (incorporated by reference to Exhibit
    10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on August 26, 2024 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.44</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324001666/ex10x1.htm">Securities
    Purchase Agreement, dated December 6, 2024 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K
    filed with the Securities and Exchange Commission on December&nbsp;6, 2024 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.45</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324001666/ex10x2.htm">Security
    Agreement, dated December&nbsp;6, 2024 (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with
    the Securities and Exchange Commission on December&nbsp;6, 2024 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.46</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324001666/ex10x3.htm" STYLE="-sec-extract: exhibit">Subsidiary
    Guarantee, dated December&nbsp;6, 2024 (incorporated by reference to Exhibit&nbsp;10.3 to the Current Report on Form 8-K filed with
    the Securities and Exchange Commission on December&nbsp;6, 2024 (File No.&nbsp;001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.47</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000107997324001666/ex10x4.htm" STYLE="-sec-extract: exhibit">Form
    of Support Agreement, dated December&nbsp;6, 2024 (incorporated by reference to Exhibit&nbsp;10.4 to the Current Report on Form 8-K
    filed with the Securities and Exchange Commission on December&nbsp;6, 2024 (File No.&nbsp;001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000155837024005902/scpx-20231231xex21d1.htm">List
    of Subsidiaries (incorporated by reference to Exhibit 21.1 to the Annual Report on Form 10-K filed with the Securities and Exchange
    Commission on April 26, 2024 (File No. 001-35994))</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex23x1.htm">Consent of Independent Registered Public Accounting Firm (BDO USA, P.C.)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex5x1.htm">Consent of Blank Rome LLP (contained in Exhibit 5.1)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_poa">Power of Attorney (reference is made to the signature page hereto)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107*</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex107.htm">Filing fee table</A></FONT></TD></TR></TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;___________________</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">*</TD><TD>Filed herewith.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">#</TD><TD>Management contract or compensatory plan or arrangement required to be identified pursuant to Item 15(a)(3) of this report.</TD></TR></TABLE>


<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif;   text-transform: uppercase; letter-spacing: 0.6pt; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Pursuant to the requirements of the Securities Act, the registrant
has duly caused this registration statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the
Morrisville, North Carolina, on December&nbsp;27, 2024.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt"><B>SCORPIUS HOLDINGS, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Jeffrey Wolf</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 53%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 39%"><FONT STYLE="font-size: 10pt">Jeffrey Wolf</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif;   text-transform: uppercase; letter-spacing: 0.6pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; letter-spacing: 0.6pt; text-align: center"><A NAME="a_poa"></A>POWER
OF ATTORNEY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature
appears below hereby constitutes and appoints Jeffrey Wolf and/or William Ostrander, as his true and lawful agent, proxy and attorney-in-fact,
with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to (i) act on,
sign and file with the Securities and Exchange Commission any and all amendments (including post-effective amendments) to this registration
statement together with all schedules and exhibits thereto and any subsequent registration statement filed pursuant to Rule 462(b) under
the Securities Act of 1933, as amended, together with all schedules and exhibits thereto, (ii) act on, sign and file such certificates,
instruments, agreements and other documents as may be necessary or appropriate in connection therewith, (iii) act on and file any supplement
to any prospectus included in this registration statement or any such amendment or any subsequent registration statement filed pursuant
to Rule 462(b) under the Securities Act of 1933, as amended, and (iv) take any and all actions which may be necessary or appropriate to
be done, as fully for all intents and purposes as he might or could do in person, hereby approving, ratifying and confirming all that
such agent, proxy and attorney-in-fact or any of his substitutes may lawfully do or cause to be done by virtue thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Pursuant to the requirements of the Securities Act, this registration
statement on Form S-1 has been signed by the following persons in the capacities and on the dates indicated.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 25%">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Jeffrey Wolf</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer,</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">December&nbsp;27, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Jeffrey Wolf</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0">President and Chairman of the Board</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0">(Principal Executive Officer)</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ William L. Ostrander</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer and Secretary</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">December&nbsp;27, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">William L. Ostrander</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(Principal Financial and Principal Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ John Monahan, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">December&nbsp;27, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">John Monahan, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ John K.A. Prendergast, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">December&nbsp;27, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">John K.A. Prendergast, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Edward B. Smith, III</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">December&nbsp;27, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Edward B. Smith, III</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 9pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
